10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended :                                    September 30, 2012                                                   

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                                                               to                                                       

Commission File Number:                                              000-49901                                                

NATURALNANO, INC.

(Exact name of registrant as specified in its charter)

Nevada	87-0646435
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
11 Schoen Place, Pittsford NY	14534
(Address of principal executive offices)	(Zip Code)

585-267-4848

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.                                                                         Yes x No ¨

Indicate by checkmark if the registrant has submitted electronically and posted on its Website, if any, every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).              Yes x     No   o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

69,429,199 as of November 16, 2012

Table of Contents

PART I—FINANCIAL INFORMATION
	Item 1.	Financial Statements (unaudited)
		Consolidated Balance Sheets	3
		Consolidated Statements of Operations	4
		Consolidated Statement of Stockholders Deficiency	5
		Consolidated Statements of Cash Flows	6
		Notes to Consolidated Financial Statements	7
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
		Note Regarding Forward-Looking Statements	16
	Item 4.	Controls and Procedures	24
PART II—OTHER INFORMATION
	Item 1.	Legal Proceedings	25
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25
	Item 3.	Defaults Upon Senior Securities	25
	Item 4.	Mine Safety Disclosures	26
	Item 5.	Other Information	26
	Item 6.	Exhibits	27
SIGNATURES			28

2

PART I—FINANCIAL INFORMATION

Item 1.  Financial Statements

NATURALNANO, INC.

CONSOLIDATED BALANCE SHEETS

	September 30,			December 31,
	2012			2011
	(Unaudited)
Assets
Current assets:
Cash	$	-		$	1,732
Accounts receivable		8,885			11,536
Inventory		24,875			20,593
Prepaid expenses and other current assets		11,370			10,033
Total current assets		45,130			43,894
Property and equipment, net		4,997			44,451
Total non-current assets		4,997			44,451
Total Assets	$	50,127		$	88,345
Liabilities and Stockholders' Deficiency
Liabilities
Current liabilities:
Notes Payable (Note 2)	$	3,862,972		$	4,433,557
Accounts payable		524,459			498,080
Accrued expenses		86,350			98,851
Accrued interest		361,769			307,283
Accrued payroll		855,157			736,181
Deferred revenue		70,000			70,000
Registration rights liability		82,489			82,489
Derivative liability		21,124			21,658
Total current liabilities		5,864,320			6,248,099
Other long term liabilities		30,000			34,000
Total Liabilities		5,894,320			6,282,099
Preferred Stock - $.001 par value, 10 million shares authorized
Series B - issued and outstanding 161,250 at September 30, 2012 with an aggregate liquidation preference of $322		22,204			-
Series C - issued and outstanding 4,214,793 at September 30, 2012 with an aggregate liquidation preference value of $8,455		145,739			-
Stockholders’ Deficiency
Preferred Stock - $.001 par value, 10 million shares authorized
Series B - issued and outstanding  647,500 at December 31, 2011 with an aggregate liquidation preference of $1,295		-			648
Series C - issued and outstanding 4,250,000 at December 31, 2011 with an aggregate liquidation preference value of $8,500		-			4,250
Common Stock - $.001 par value 294,117,647 authorized, issued and outstanding 60,652,399 and 23,403,670, respectively		60,652			17,138
Additional paid in capital		21,184,872			19,983,595
Noncontrolling interest in subsidiary		14,264			14,264
Accumulated deficit		(27,271,924	)		(26,213,649	)
Total stockholders' deficiency		(6,012,136	)		(6,193,754	)
Total Liabilities and Stockholders' Deficiency	$	50,127		$	88,345

See notes to consolidated financial statements

3

NATURALNANO, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

	For the three months ended						For the nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Income:
Revenue	$	16,158		$	30,136		$	86,581		$	233,951
Cost of goods sold		3,667			12,399			17,653			70,351
Gross profit		12,491			17,737			68,928			163,600
Operating expenses:
Research and development		21,377			39,556			90,084			122,741
General and administrative		93,549			115,069			268,437			306,766
		114,926			154,625			358,521			429,507
Loss from Operations		(102,435	)		(136,888	)		(289,593	)		(265,907	)
Other income (expense):
Interest expense, net		(87,149	)		(97,165	)		(295,650	)		(281,852	)
Net gain on derivative liability		534			80,179			534			41,927
Net loss on forgiveness/modification of debt		(163,566	)		(30,000	)		(473,566	)		(21,050	)
Gain  on insurance settlement		-			-			-			31,589
		(250,181	)		(46,986	)		(768,682	)		(229,386	)
Consolidated net loss		(352,616	)		(183,874	)		(1,058,275	)		(495,293	)
Less: Consolidated net (income) loss attributable to noncontrolling interest in subsidiary		-			7,297			-			(1,813	)
Consolidated net loss attributable to the controlling interest	$	(352,616	)	$	(176,577	)	$	(1,058,275	)	$	(497,106	)
Less: Preferred stock conversion inducement		-			-			(12,235	)		-
Consolidated net loss attributable to common shareholders	$	(352,616	)	$	(176,577	)	$	(1,070,510	)	$	(497,106	)
Loss per common share - basic and diluted	$	(0.01	)	$	(0.01	)	$	(0.03	)	$	(0.03	)
Weighted average shares outstanding		55,644,823			18,003,314			42,169,055			15,340,376

See notes to consolidated financial statements

4

NATURALNANO, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIENCY

(unaudited)

											Additional						Non-controlling
	Common Stock				Preferred Stock						Paid-in			Accumulated			Interest		Stockholders’
	Shares		Amount		Shares			Amount			Capital			Deficit			in Subsidiary		(Deficiency)
Balance at December 31, 2011		23,403,671	$	23,403		4,897,500		$	4,898		$	19,977,330		$	(26,213,649	)	$	14,264	$	(6,193,754	)
Grant of common stock for services @:$0.005 to $.0007 per share		1,764,706		1,765								9,035								10,800
Issuance of common stock as interest payment		6,221,156		6,221								234,943								241,164
Warrant issued for services												8,720								8,720
Shares issued on debt conversion		13,594,382		13,594								969,991								983,585
Series B preferred shares converted to common shares		10,035,294		10,035		(486,250	)		(486	)		(9,549	)							-
Series C preferred shares converted to common shares		5,633,191		5,633		(35,207	)		(35	)		(5,598	)							-
Transfer of preferred shares to temporary equity						(4,376,043	)		(4,376	)										(4,376	)
Net income (loss) for the nine months ended 09/30/12															(1,058,275	)		-		(1,058,275	)
Balance at September 30, 2012		60,652,399	$	60,652		-		$	-		$	21,184,872		$	(27,271,924	)	$	14,264	$	(6,012,136	)

See notes to consolidated financial statements

5

NATURALNANO, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

	For the nine months ended
	September 30,
	2012			2011
Cash flows from operating activities:
Net loss attributable to controlling interest	$	(1,058,275	)	$	(497,106	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		39,454			75,730
Amortization of discount on convertible notes		-			1,799
Amortization of deferred financing costs		-			3,815
Non-cash gain on forgiveness of debt		-			(38,950	)
Fair value adjustment of derivative liabilities		(534	)		(41,927	)
Issuance of stock for services		10,800			33,150
Issuance of stock for interest		24,221			415,650
Issuance of warrants for services		8,720			8,720
Loss on modification of debt		473,566			60,000
Income (loss) from non-controlling interest in subsidiary		-			1,813
Changes in operating assets and liabilities:
Increase  in inventory		(4,282	)		(39,790	)
Increase in accounts receivable		2,651			1,587
Decrease (increase)  in other current assets		(1,337	)		5,303
(Decrease) increase in accounts payable, accrued payroll and accrued expenses		404,284			(62,233	)
Decrease in deferred revenue		-			(2,270	)
Decrease in other liability		(4,000	)		(4,500	)
Net cash used in operating activities		(104,732	)		(79,209	)
Cash flows from financing activities:
Proceeds from senior secured promissory notes		103,000			80,000
Proceeds from unsecured promissory notes		-			18,080
Payment on unsecured promissory notes		-			(18,080	)
Net cash provided by financing activities		103,000			80,000
Increase (decrease) in cash		(1,732	)		791
Cash at beginning of period		1,732			6,861
Cash at end of period	$	-		$	7,652
Supplemental disclosure of cash flow information:
Cash paid for interest during the period	$	-		$	5,671
Schedule of non-cash investing and financing activities:
Common stock issued for convertible notes	$	983,585		$	80,000
Common stock issued for accrued interest	$	216,943		$	-
Conversion of preferred shares into common shares	$	15,669		$	13,200
Transfer of preferred shares to temporary equity	$	4,376		$	-

See notes to consolidated financial statements

6

NATURALNANO, INC.

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2011 and 2010

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.   PRINCIPAL BUSINESS ACTIVITY AND SIGNIFICANT ACCOUNTING POLICIES

Interim Financial Statements

The consolidated financial statements as of September 30, 2012 and for the three and nine months ended September 30, 2012 and 2011 are unaudited. However, in the opinion of management of the Company, these financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary to present fairly the financial position and results of operations for such interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results to be obtained for a full year. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X for smaller reporting companies.  Accordingly, these financial statements do not include all of the information required by U.S. generally accepted accounting principles for complete financial statements.  These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011. Certain prior period amounts have been adjusted to reflect the Company’s 1-for-17 reverse stock split (see Note 10 Reverse Stock Split, for further details).

Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, we evaluate such estimates. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.

Fair Value of Financial Instruments

Financial instruments include cash and cash equivalents, accounts payable and accrued expenses, notes payable, and derivative liabilities. Fair values for all instruments except for derivative liabilities and convertible notes payable were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values or they are receivable or payable on demand. The fair value of the derivative liabilities is discussed further in Note 6. The fair value of the Company’s convertible notes payable is estimated be less than the carrying value at September 30, 2012 based upon overall value of the company, lack of authorized shares underlying the conversion of the instruments, and the lack of liquid market for the volume of shares issuable upon conversion of the entire outstanding balance.

Basis of Consolidation

The consolidated financial statements include the accounts of NaturalNano, Inc. (“NaturalNano” or the “Company”), a Nevada corporation, and its wholly owned subsidiary NaturalNano Research, Inc. (“NN Research”) a Delaware corporation. As of April 20, 2010 the consolidated financial statements reflect the acquisition of a 51% controlling interest in Combotexs, LLC, (“Combotexs”), a privately held New York limited liability company, pursuant to the terms of the Equity Purchase Agreement executed with Worldwide Medical Solutions LLC (“WMS”) (Refer to Note 4). All significant inter-company accounts and transactions have been eliminated in consolidation.

Description of the Business

NaturalNano (the “Company”), located in Pittsford, New York, is engaged in the development and commercialization of material science technologies with an emphasis on additives to polymers and other industrial and consumer products by taking advantage of technology advances developed in-house. The Company’s current activities are directed toward research, development, production and marketing of its proprietary technologies relating to the treatment and separation of nanotubes from halloysite clay and the development of related commercial applications for:

• cosmetics, health and beauty products

• polymers, plastics and composites

Combotexs was a technology company organized on October 28, 2009 that marketed Error Prevention/Safety Checklist Boards and Safety Training to hospitals and other industries such as healthcare, petrochemical and mining.  Combotexs also had certain marketing and distribution agreements for various household products.  The Company acknowledges the acquisition of Combotexs as a short term source for revenue, cash flow and a method of incorporating nanotubes found in halloysite clay into Combotexs products.

7

During the fourth quarter of 2011, the Company determined that the relationship with Combotexs was not operating in the manner it was intended. The sales were not to the volume expected and the continued operations, as structured, were not sustainable. During the month of December, the board of directors authorized the Company CEO to wind down the operations of Combotexs resulting in a write down of assets and the inventory revalued and assumed by NaturalNano. No further activity will occur with Combotexs beyond December 31, 2011 and the entity is expected to be legally dissolved in 2012.

During the fourth quarter of 2011, the Company entered into a supply agreement with another company, which is 50% owned by NaturalNano’s CEO, to manufacture and sell Error Prevention/Safety Checklist Boards which the related party will then market to the end user. NaturalNano will continue to outsource the manufacture of the boards to a third-party and then re-sell them to the new company. Accordingly, the Company will still have continuing cash flows from the business in 2012 and beyond.

NaturalNano is domiciled in the state of Nevada as a result of the merger with Cementitious Materials, Inc., (“CMI”), which was completed on November 29, 2005.

Liquidity and Going Concern

Going Concern – The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company incurred a net loss for the nine months ended September 30, 2012 of $1,058,275 and had negative working capital of $5,184,193 and a stockholders’ deficiency of $6,012,136 at September 30, 2012. Since inception the Company’s growth has been funded through a combination of convertible debt from private investors and from cash advances from its former parent and majority shareholder Technology Innovations, LLC. These factors, among others, may indicate that the Company will be unable to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations, to obtain additional financing, renegotiate the terms of existing financing obligations and ultimately to attain successful operations. The ability to successfully achieve those items is uncertain.

As of September 30, 2012, the Company continued to require waivers for debt covenant violations and extensions of maturity dates. Refer to Note 2 for lenders waivers and maturity extensions received from the lenders.

QETC rebate for fiscal year ended December 31, 2009

The QETC tax rebate for 2009 had been in audit since its filing in September of 2010. The Company received notice in March 2011 that the audit was complete and that the rebate for 2009 would be for $60,073. NaturalNano received the first payment of $43,615 in March of 2011 and that amount was reflected in the financial statements for the first quarter of 2011. The Company received the final payment of $16,458 on April 14, 2011 and that amount was reflected in the financial statements for the second quarter of 2011. These amounts were presented as a reduction of general and administrative expenses.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

Loss Per Share

Basic loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share gives effect to dilutive convertible preferred stock, convertible debt, options and warrants outstanding during the period. Shares to be issued upon the exercise of these instruments have not been included in the computation of diluted loss per share as their effect is anti-dilutive based on the net loss incurred.

As of September 30, 2012, there were approximately 2.7 billion shares underlying preferred stock, convertible debt, outstanding options and warrants that could potentially dilute future earnings. As the company has only 294,117,647 common shares authorized, of which only approximately 225 million are available for future issuance, there is not an adequate number of common shares authorized to satisfy all outstanding preferred stock, convertible debt and outstanding option and warrants. These potentially dilutive shares have been limited by certain debt and equity agreements with Platinum, Platinum Advisors, Longview and Technology Innovations LLC (“TI”). These agreements provide limitations on the conversion of the dilutive instruments such that the number of shares of Common Stock that may be acquired by the holder upon conversion of such instruments shall be limited to ensure that following such conversion the total number of shares of Common Stock then beneficially owned by the holder does not exceed 4.99% of the total number of issued and outstanding shares of Common Stock.

8

2.  NOTES PAYABLE

Notes payable consisted of the following:

Notes Payable	September 30, 2012		December 31, 2011
Senior Secured Convertible Notes		3,134,415		3,819,000
Senior Secured Promissory Notes		477,557		374,557
Subordinated Secured Convertible Note at Face Value, net of discount of $0 and $1,799		251,000		240,000
Total	$	3,862,972	$	4,433,557

Senior Secured Convertible Notes

As of September 30, 2012, the Company had $3,134,415 in principal that was outstanding and past due under the terms of the Senior Secured Convertible Notes to Platinum Partners Long Term Growth IV (“Platinum”), Platinum Advisors and Longview Special Financing, Inc. (“Longview”). The Company entered into various Senior Secured Convertible Notes and Promissory Note obligations during the period from 2007 through 2012 with Platinum, Platinum Advisors and Longview, the holders of the Company’s primary debt obligations since 2007. The outstanding principal and all accrued and unpaid interest on these obligations was due and payable in full on various dates beginning March 6, 2009. Platinum and Platinum Advisors have granted waivers of default, extended the due dates of all the outstanding principal balances to January 31, 2013, and waived the application of the 16% default interest rate. In consideration for their forbearance effective April 16, 2012, Platinum Advisors will be paid $125,000 which was added to the principal balance of the note. This forbearance was considered and accounted for as a modification of debt and a loss of $125,000 for the three months ending June 30, 2012 and reported in the statement of operations. By way of two separate forbearance agreements dated January 1, 2012 and April 16, 2012, Longview has granted waivers of default, extended the due dates of all the outstanding principal balances to July 1, 2012, and waived the application of the 16% default interest rate. Additionally, Longview waived the automatic adjustment of the conversion rate for past and future S-8 stock issuances made for compensation and payments of services. In consideration for their forbearance, Longview will be paid $50,000 for the forbearance which was added to the principal balance of the note. These forbearance amounts were considered and accounted for as a modification of debt and a loss of $50,000 for the three months ending March 31, 2012 and June 30, 2012 respectively and reported in the statement of operations. By way of a third forbearance agreement dated June 15, 2012, Longview has granted waivers of default, extended the due dates of all the outstanding principal balances to September 30, 2012, and waived the application of the 16% default interest rate. In consideration for their forbearance, Longview will be paid $30,000 for the forbearance which was added to the principal balance of the note. This forbearance amount was considered and accounted for as a modification of debt and recorded as a loss of $30,000 for the three months ending June 30, 2012 in the statement of operations.

By way of forbearance agreements effective as of September 30, 2012, Platinum, Platinum Advisors and Longview have granted waivers of default, extended the due dates of all the outstanding principal balances to January 30 or 31, 2013, and waived the application of the 16% default interest rate. In consideration for their forbearance, the conversion features of these notes have been changed from a fixed conversion rate of $0.085 per share to a variable rate of 75% of the lowest of the 1, 5, or 10 day volume weighted average price (VWAP) for the Company’s common stock. These adjustments are not expected to have a significant impact on the expected cash flows of the debt as a result of the lack of shares issuable to convert the entire balance and the uncertainty of the Company’s ability to repay the full amounts due. Accordingly, the obligations were not recorded at fair value at the date of modification, which is estimated to be less than the carrying value both before and after the modification. The revised conversion price was considered when determining the value of the derivative liability associated with this debt. Also in consideration for their forbearance the conversion rate of the Preferred C and Preferred B shares held by Platinum and Longview has been changed from 9.41 common shares per share of preferred to 160 common shares per share of preferred. Due to there not being sufficient common shares authorized to satisfy the conversion of all the preferred shares, they are required to be recorded as temporary equity at their issuance date fair value which resulted in an increase in the balance presented for preferred stock of $163,566. This amount was recognized as a loss on modification of debt on our consolidated statement of operations for the three month period ended September 30, 2012.

During the first six months of 2012, until the Reverse Stock Split (see Note 10), the Company issued 1,729,412 and 11,053,941 split adjusted shares of common stock to Platinum in payment of $147,000 of interest expense obligations and $939,585 of principal obligations, respectively, on the Senior Secured Convertible Notes. In accordance with the debt agreement, these shares were issued to Platinum using a split adjusted conversion price of $0.085 per common share. Subsequent to the Reverse Stock Split, the Company issued 3,967,626 shares of common stock to Platinum in payment of $25,393 of interest expense obligations on the Senior Secured Convertible Notes. These shares were issued to Platinum using a conversion price of $0.0064 per common share. The issuance of shares in excess of the conversion rate in place at the time of $0.085 were considered an inducement to convert and resulted in an expense of $24,221 based on the market value at the time the excess shares were issued. This expense is included in interest expense for the three months ended June 30, 2012.

9

Senior Secured Promissory Notes

As of September 30, 2012, the Company had $477,557 in principal that was outstanding and past due under the terms of Senior Secured Promissory Notes to Platinum Partners Long Term Growth IV (“Platinum”) and Longview Special Financing, Inc. (“Longview”). All borrowings under the Senior Secured Promissory Notes bear interest at the rate of 8% per annum and are payable on January 30 or 31, 2013 in accordance with the forbearance agreements mentioned above.

Additions to Senior Secured Promissory Notes in 2012 are as follows:

- On February 10, 2012, the Company borrowed $25,000 from Platinum.

- On March 5, 2012, the Company borrowed $12,000 from Platinum.

- On April 16, 2012, the Company borrowed $15,000 from Platinum.

- On May 11, 2012, the Company borrowed $20,000 from Platinum.

- On July 20, 2012, the Company borrowed $7,000 and $24,000 respectively from Platinum and Longview.

Subordinated Secured Convertible Note

As of March 1, 2011 the Company had $225,000 in principal that was outstanding and due under the terms of the 10% Subordinated Secured Convertible Promissory Agreement (the “Convertible Note”) with Cape One Financial LP (“Cape One”). On March 15, 2011 the Company and Cape One entered into a forbearance agreement which altered the due date of the Convertible Note from March 1, 2011 to June 30, 2011.  As consideration for this forbearance, Cape One will be paid $30,000 which was added to the principal balance of the note.  In addition, the interest rate on the outstanding amount during the forbearance period will be adjusted from 10% to 18%. The forbearance agreement was considered and accounted for as a modification of debt and resulted in a loss of $30,000 for the three months ended March 31, 2011 reported in the statement of operations. Effective June 30, 2011, the Company and Cape One entered into a forbearance agreement which altered the due date of the Convertible Note from June 30, 2011 to October 1, 2011. Effective September 30, 2011, the Company and Cape One entered into another forbearance agreement which altered the due date of the Convertible note from October 1, 2011 to November 22, 2011. As consideration for this forbearance, Cape One will be paid $30,000 which will be added to the principal balance of the note. This forbearance agreement was considered and accounted for as a modification of debt and resulted in a loss of $30,000 for the three months ended September 30, 2011 reported in the statement of operations. Effective January 17, 2012, the Company entered into a forbearance agreement which extends the due date of all the outstanding principal and interest balances to April 16, 2012.  As consideration for this forbearance, Cape One will be paid $25,000 which will be added to the principal balance of the note. The forbearance agreement was considered and accounted for as modification of debt and a loss of $25,000 for the three months ending March 31, 2012 and reported in the statement of operations. Effective April 16, 2012, the Company entered into a forbearance agreement which extends the due date of all the outstanding principal and interest balances to July 01, 2012. Effective June 30, 2012, the Company entered into a forbearance agreement which extends the due date of all the outstanding principal and interest balances to September 30, 2012.  As consideration for this forbearance, Cape One will be paid $30,000 which will be added to the principal balance of the note. The forbearance agreement was considered and accounted for as modification of debt and a loss of $30,000 for the three months ending June 30, 2012 and reported in the statement of operations.

By way of a forbearance agreement effective as of September 30, 2012, Cape One has extended the due date of all the outstanding principal and interest balances to January 31, 2013.  In consideration for this forbearance, the conversion feature of this notes have been changed from a fixed conversion rate of $0.085 per share to a variable rate of 75% of the lowest of the 1, 5, or 10 day VWAP for the Company’s common stock. These adjustments are not expected to have a significant impact on the expected cash flows of the debt as a result of the lack of shares issuable to convert the entire balance and the uncertainty of the Company’s ability to repay the full amounts due. Accordingly, the obligations were not recorded at fair value at the date of modification, which is estimated to be less than the carrying value both before and after the modification. The revised conversion price was considered when determining the value of the derivative liability associated with this debt.

During the first six months of 2012, until the Reverse Stock Split (see Note 10), the Company issued 352,941 and 524,118 shares of common stock to Cape One in payment of $30,000 of principal obligations and $44,550 of interest expense obligations, respectively, on the 10% Convertible Note. In accordance with the debt agreement, these shares were issued to Cape One using a split adjusted conversion price of $0.085 per common share. Subsequent to the Reverse Stock Split, the Company issued 2,187,500 shares of common stock to Cape One in payment of $14,000 of principal obligations on the 10% Convertible Note. These shares were issued to Cape One using a conversion price of $0.0064 per common share.

3.  REGISTRATION RIGHTS AGREEMENT

On March 7, 2007, the Company entered into a Registration Rights Agreement with the Agent and the other investors, pursuant to which the Company agreed to prepare and file within 60 days of the March 7, 2007 agreement, a registration statement for resale under the Securities Act of 1933, the common stock issuable upon the exercise of the Warrants, in payment of interest on, or upon conversion of, the Notes. The Company further agreed to use its best efforts to cause the Registration Statement to be declared effective 120 days following the March 7, 2007 agreement date, or within 150 days if the Company receives a comment letter from the SEC, and to maintain such Registration Statement for the two year period following this date. This agreement allows for liquidated damages based on a daily amount of 0.0333% of the principal amount of the notes relating to the common stock issuable upon conversion of the Notes included in the Registration Statement.

10

As of September 30, 2012, the registration statement had not been updated with the requisite SEC filings and as such, the Company was in default of this provision of the Registration Rights Agreement. The lenders have provided the Company with a forbearance agreement related to this default through November 22, 2011. The Company recorded a total of $146,028 in such liquidated damages as of December 17, 2007, the date the registration statement was declared effective. As of December 31, 2007, $63,539 of this obligation was paid in cash and $82,489 was recorded as an accrued liability. The lender has the option to settle the liquidated damages in common stock valued at the average price for the five days prior to the end of a payment period. At September 30, 2012 and December 31, 2011 the outstanding balance for this obligation was $82,489.

4.  51% ACQUISITION of COMBOTEXS, LLC

On April 20, 2010 the Company acquired a 51% interest in Combotexs, LLC, (“Combotexs”), a privately held   New York   limited liability company, pursuant to the terms of an Equity Purchase Agreement executed with Worldwide Medical Solutions LLC (“WMS”) the sole member of Combotexs. Combotexs is a technology company that has had minimal revenue since its inception in October 2009 and markets Error Prevention/Safety Checklist Boards and Safety Training to hospitals and other industries such as healthcare, petrochemical and mining. The Company acknowledges the acquisition of Combotexs as a short term source for revenue, cash flow and a method of incorporating nanotubes found in halloysite clay into Combotexs products.

As a result of the changes in the relationship with Combotexs, the carrying values of the related assets as of December 31, 2011 were evaluated. Certain inventory was sold to the related party, certain demonstration inventory was written off resulting in a $36,875 charge to cost of goods sold, and future cash flows were determined to be inestimable and as a result, the Goodwill was impaired to $0 value resulting in an impairment loss of $80,332 during the year ended December 31, 2011.

During the fourth quarter of 2011, the Company entered into a supply agreement with another company, which is 50% owned by NaturalNano’s CEO, to manufacture and sell Error Prevention/Safety Checklist Boards which the related party will then market to the end user. NaturalNano will continue to outsource the manufacture of the boards to a third-party and then re-sell them to the new company. Accordingly, the Company will still have continuing cash flows from the business in 2012 and beyond.

5. SEGMENT INFORMATION

The Company's reportable segments are strategic business units that offer different products and services. The Company’s reportable segments are organized, managed and internally reported separately because each business requires different technology and marketing strategies. The Company currently has two operating segments, Nanotechnology and Medical Boards.  A summary of the two segments is as follows:

Nanotechnology	Research, development, production and marketing of its proprietary technologies relating to the treatment and separation of nanotubes from halloysite clay and the development of related commercial applications for cosmetics, health and beauty products and polymers, plastics and composites.
Medical Boards	Production of Error Prevention/Safety Checklist Boards for sale to a related party.

The accounting policies of the segments are the same as those described in the summary of significant accounting policies of the Company.  The Company accounts for intersegment sales and transfers as if the sales or transfers were to third parties, that is, at current market prices. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein.  For purposes of determining segment loss, corporate overhead is primarily included in NaturalNano, other than direct expense of Combotexs.  Approximate information concerning the Company’s operations by reportable segment as of and for the three and nine months ended September 30, 2012 and September 30, 2011 is as follows:

11

	Nanotechnology						Medical Boards					Consolidated
	For the three months ended						For the three months ended					For the three months ended
	September 30,						September 30,					September 30,
	2012			2011			2012		2011			2012			2011
Segment profit (loss) from operations	$	(108,892	)	$	(124,575	)	$	6,457	$	(12,313	)	$	(102,435	)	$	(136,888	)
Revenues from external customers	$	6,783		$	2,000		$	9,375	$	28,136		$	16,158		$	30,136
Revenues from intersegment sales	$	-		$	2,580		$	-	$	-		$	-		$	2,580
Interest expense and amortization of debt discount	$	87,149		$	24,370		$	-	$	-		$	87,149		$	24,370
Depreciation and amortization	$	5,041		$	22,457		$	-	$	240		$	5,041		$	22,697
Significant non-cash items:
Equity based payments	$	-		$	13,107		$	-	$	-		$	-		$	13,107
Loss on modification of debt	$	163,566		$	-		$	-	$	-		$	163,566		$	-
	Nanotechnology						Medical Boards					Consolidated
	For the nine months ended						For the nine months ended					For the nine months ended
	September 30,						September 30,					September 30,
	2012			2011			2012		2011			2012			2011
Segment profit (loss) from operations	$	(307,070	)	$	(284,368	)	$	17,477	$	18,461		$	(289,593	)	$	(265,907	)
Revenues from external customers	$	55,331		$	71,460		$	31,250	$	162,491		$	86,581		$	233,951
Revenues from intersegment sales	$	-		$	14,760		$	-	$	-		$	-		$	14,760
Interest expense and amortization of debt discount	$	295,650		$	209,056		$	-	$	-		$	295,650		$	209,056
Depreciation and amortization	$	39,454		$	75,010		$	-	$	720		$	39,454		$	75,730
Significant non-cash items:
Equity based payments	$	10,800		$	50,270		$	-	$	-		$	10,800		$	50,270
Loss on modification of debt	$	473,566		$	-		$	-	$	-		$	473,566		$	-

Geographic Areas - The Company had no revenue and no long-lived assets in any country other than the United States for any period presented.

Major Customers - During the three months ended September 30, 2012, the Company derived 57% (representing sales to a related party included in the Medical Boards operating segment) and 17% (included in the Nanotechnology operating segment) of its revenue from two different customers. During the nine months ended September 30, 2012, the Company derived 36% (representing sales to a related party included in the Medical Boards operating segment) and 51% (included in the Nanotechnology operating segment) of its revenue from two different customers.

6.  DERIVATIVE LIABILITY

The Company’s derivative liabilities as of September 30, 2012 and December 31, 2011 are as follows:

· The debt conversion feature embedded in the Senior Secured Convertible Notes entered into in March 2007, August 2008, September 2008 and October 2008 which contains anti-dilution provisions that would be triggered if the Company issued instruments with rights to the Company’s common stock at prices below this exercise price. Additionally, there are not sufficient authorized common shares to satisfy the conversion of the total debt balance.

· The debt conversion feature and the 2,647,059 million warrants exercisable at $0.0425 per share (split adjusted) granted in connection with the 10% Subordinated Secured Convertible Note entered into in November 2009.  These agreements contain anti-dilution provisions that would be triggered if the Company issued instruments with rights to the Company’s common stock at prices below the exercise price. Additionally, there are not sufficient authorized common shares to satisfy conversion of the total debt balance and warrants.

· The 882,353 warrant shares granted to the CEO of the Company at an exercise price of $0.17 per share on January 2011 which vest over three years.

12

The fair value of the derivatives is as follows:

Derivative Liability	September 30, 2012		December 31, 2011
8% Notes conversion feature	$	17,120	$	20,531
10% Notes conversion feature and warrants		4,004		1,127
CEO warrants		-		-
Total	$	21,124	$	21,658

 Fair Value Valuation Hierarchy Measurement

ASC 820 establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:

· Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.

· Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

· Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to measure assets and liabilities at fair value.

A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

The derivative liabilities are measured at fair value using certain estimated factors such as volatility and probability and are classified within Level 3 of the valuation hierarchy. The following table provides a roll forward of the liabilities carried at fair value measured using significant unobservable inputs (level 3).

	For the nine months ended
	September 30,
	2012			2011
Fair value – beginning	$	21,658		$	76,667
Loss  recognized in Q1		-			67,914
Gain recognized in Q2		-			(29,662	)
Gain recognized in Q3		(534	)		(80,179	)
Fair value – ending	$	21,124		$	34,740

7.  STOCKHOLDERS EQUITY

On January 3, 2011, the Chief Executive Officer, Mr. Jim Wemett was awarded 882,353 warrant shares, each warrant share grants the right to purchase one share of common stock, at an exercise price of $0.17 per warrant share, vesting over three years. The warrants expire January 3, 2016 and contain a cashless exercise provision. The fair value of the warrant on the date of grant was determined using the Black-Scholes model and was measured on the date of grant at $34,879. An expected volatility assumption of 150% has been used based on the volatility of the Company’s stock price utilizing a look-back basis and the risk-free interest rate of 3.36% has been derived from the U.S. treasury yield. The market price of the Company’s common stock on January 3, 2011 was $0.0476 per share. The expiration date used in the valuation model aligns with the warrant life of five years. The dividend yield was assumed to be zero. The fair value of the warrant will be recorded monthly over the 36 month life of the warrant. During the three and nine months ended September 30, 2012, the Company recorded $2,907 and $8,720 respectively of expense for the vested portion of the warrant.

During the first six months of 2012, until the Reverse Stock Split (see Note 10), the Company issued 1,729,412 and 11,053,941 split adjusted shares of common stock to Platinum in payment of $147,000 of interest expense obligations and $939,585 of principal obligations, respectively, on the Senior Secured Convertible Notes. In accordance with the debt agreement, these shares were issued to Platinum using a split adjusted conversion price of $0.085 per common share. Subsequent to the Reverse Stock Split through September 30, 2012, the Company issued 3,967,626 shares of common stock to Platinum in payment of $25,393 of interest expense obligations on the Senior Secured Convertible Notes. These shares were issued to Platinum using a conversion price of $0.0064 per common share. The issuance of shares in excess of the conversion rate in place at the time of $0.085 were considered an inducement to convert and resulted in an expense of $24,221 based on the market value at the time the excess shares were issued. This expense is included in interest expense for the three months ending June 30, 2012.

13

Prior to the Reverse Stock Split (see Note 10), in 2012 Alpha Capital Anstalt converted 450,000 preferred B shares held by Longview Special Finance into 4,235,294 common shares respectively. Subsequent to the Reverse Stock split on June 18, 2012 Alpha Capital Anstalt converted 12,500 preferred B shares held by Longview Special Finance into 2,000,000 common shares. As the post-split conversion rate for the shares held by Longview Special Finance was 9.41 common shares per 1 share of preferred stock, the excess shares were recorded as an expense attributable to common stockholders in the statement of operations for the three months ended June 30, 2012 at their conversion date market value of $12,235. As a condition of forbearance agreements entered into in Q3 2012, the conversion rate for all outstanding shares of preferred stock was adjusted to 160 common shares for each share of preferred (Note 2). Subsequent to this modification, in Q3 Alpha Capital Anstalt converted 23,750 preferred B shares held by Longview Special Finance into 3,800,000 common shares. Also subsequent to this modification, in Q3 Platinum converted 35,207 preferred C shares into 5,633,191 common shares.

During the first six months of 2012, until the Reverse Stock Split (see Note 10), the Company issued 877,059 shares of common stock to Cape One in payment of $44,500 of interest expense obligations and $30,000 of principal obligations on the Convertible Notes. In accordance with the debt agreement, these shares were issued to Cape One using a conversion price of $0.085 per common share. Subsequent to the Reverse Stock Split through September 30, 2012, the Company issued 2,187,500 shares of common stock to Cape One in payment of $14,000 of principal obligations on the Senior Secured Convertible Notes. These shares were issued to Cape One using a conversion price of $0.0064 per common share.

During the first six months of 2012, the Company issued an aggregate of 1,764,706 shares of common stock to various individuals or entities in connection with professional consulting provided to the Company in an aggregate amount of $10,800.

The Company has issued warrants to purchase shares of its common stock to certain consultants and debt holders. As of September 30, 2012, there were common stock warrants outstanding to purchase an aggregate 4,247,059 shares of common stock pursuant to various warrant grant agreements. In April of 2012, 14,162 warrants originally issued to a consultant in April of 2007 expired unexercised. As a result of the Company not having sufficient shares authorized to satisfy its outstanding convertible and exercisable instruments including these warrants, these warrants should be treated as a liability recorded at their fair value. As the estimated fair value of these warrants as of September 30, 2012 is nearly $0, no liability has been recorded.

On May 20, 2011, June 8, 2011 and August 26, 2011 Alpha Capital Anstalt converted 20,000, 31,250 and 31,250 preferred shares held by Longview Special Finance into 3,200,000, 5,000,000 and 5,000,000 common shares respectively.

As there are not sufficient shares to satisfy the conversion features of all of the Company’s convertible notes payable and convertible preferred stock, the Company does not control the settlement of these convertible securities by delivery of the Company’s own common shares, resulting in the presumption of cash settlement. This results in the carrying value of the outstanding Preferred B and Preferred C shares being classified as temporary equity as of September 30, 2012.

8.  INCENTIVE STOCK PLANS

Under the Company’s 2005 Incentive Stock Plan (the “2005 Plan”), the Amended and Restated 2007 Incentive Stock Plan (the “2007 Plan”), the 2008 Incentive Stock Plan (the “2008 Plan”), the 2009 Incentive Stock Plan (the “2009 Plan”), the 2011 Stock Incentive Plan (the “2011 Plan”), and the 2012 Stock Incentive Plan (the “2012 Plan”), officers, employees, directors and consultants may be granted options to purchase the Company’s common stock at fair market value as of the date of grant. Options become exercisable over varying vesting periods commencing from the date of grant and have terms of five to ten years. The plan also provides for the granting of performance-based and restricted stock awards.  The shares of common stock underlying the plans are reserved by the Company from its authorized, but not issued common stock. Such shares are issued by the Company upon exercise by any option holder pursuant to any grant of such shares.

The Plans are authorized to grant awards as follows: the 2005 Plan is authorized to grant up to 823,530 share unit awards, the 2007 Plan is authorized to grant up to 1,000,000 share unit awards, the 2008 Plan is authorized to grant up to 47,058,824 unit share awards, the 2009 Plan is authorized to grant up to 1,176,471 unit share awards, the 2011 Plan is authorized to grant up to 1,470,589 unit share awards and the 2012 Plan is authorized to grant up to 1,764,706 unit share awards.

A summary of the option activity for the nine months ended September 30, 2012 is presented below:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Life-years
Outstanding at January 1, 2012		741,373		$	3.52		4.00
Cancelled/Forfeited		(18,236	)
Options outstanding at September 30, 2012		723,137		$	3.53		3.32
Options exercisable at September 30, 2012		723,137		$	3.53		3.32

14

9.  CONTINGENCIES

Legal Proceedings

On March 24, 2009 the Company received a demand notice from an attorney representing a group of certain former employees of the Company, including but not limited to the Company’s former President and Chief Financial Officer, demanding immediate payment of $331,265 for certain deferred compensation, severance and vacation benefits. Each of the former employees cited in the demand notice, as well as other former employees, had executed written agreements during 2008 that allowed the Company to defer certain of these compensation payments. The Company has accrued for earned and unused vacation benefits and deferred payroll costs for amounts electively deferred by these and other former employees as of December 31, 2009. The Company has retained counsel in connection with this demand and continues to evaluate this demand notice and has responded to this demand. No actions or probable settlement discussions between the parties have developed since the filing of this demand. Due to the Company’s current cash and liquidity position discussed above and the current evaluation of the items in the demand notice the timing of future payment of these outstanding amounts is uncertain. No further communication has been had regarding this notice.

During the third quarter ending September 30, 2010, two former employees, one involved in the March 24, 2009 demand, agreed to forgive the Company’s liability to them of $54,691 related to deferred compensation in exchange for shares of common stock.

10. REVERSE STOCK SPLIT

On June 14, 2012, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Nevada, to effect a 1-for-17 reverse stock split of its common stock, or the Reverse Stock Split. This action had previously been approved by the Company’s Board of Directors on March 23, 2012. As a result of the Reverse Stock Split, every seventeen shares of the Company’s pre-reverse split common stock were combined and reclassified into one share of its common stock. No fractional shares were issued in connections with the Reverse Stock Split. Stockholders who would have been entitled to receive a fractional share in connection with the Reverse Stock Split received one whole share. The par value and other terms of the common stock were not affected by the Reverse Stock Split.

The Company’s authorized shares immediately prior to the Reverse Stock Split totaled 5,000,000,000. These were adjusted to 294,117,647. The Company’s shares outstanding immediately prior to the Reverse Stock Split totaled 732,073,557. These were adjusted to 43,063,150 shares outstanding as a result of the Reverse Stock Split. The Company’s common stock began trading at its post-Reverse Stock Split price at the beginning of trading on June 14, 2012. Share, per share, and stock option amounts for all periods presented within this quarterly report on Form 10-Q and the December 31, 2011 Balance Sheet amounts for common stock and additional paid-in-capital have been retroactively adjusted to reflect the Reverse Stock Split.

11. SUBSEQUENT EVENTS

Subsequent to September 30, 2012 and prior to the filing of this report, the following occurred:

Stock Transactions

· On October 16, 2012, 5,676,800 shares of common stock were issued to Platinum Long Term Growth IV, LLC who elected to convert 35,480 shares of Series C preferred shares at the conversion rate of 160 common shares per each Series C share.

· On October 19, 2012, 3,100,000 shares of common stock were issued to Alpha Capital who elected to convert $3,720 of interest due Longview at $0.0012 per share.

15

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q and other reports that we file with the SEC contain statements that are considered forward-looking statements that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plans,” “potential,” “projects,” “continuing,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend” and similar expressions. Such forward looking statements include statements addressing operating performance, events or developments that the Company expects or anticipates will occur in the future, including statements relating to revenue realization, revenue growth, earnings, earnings per share, or similar projections. These statements estimates involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed for the reasons described in this report. You should not place undue reliance on these forward-looking statements.

You should be aware that our actual results could differ materially from those contained in the forward-looking statements due to a number of factors such as:

· the ability to raise capital to fund our operations until we generate adequate cash flow internally;

· the terms and timing of product sales and licensing agreements;

· our ability to enter into strategic partnering and joint development agreements;

· our ability to competitively market our controlled release and filled tube products;

· the successful implementation of research and development programs;

· our ability to attract and retain key personnel ;

· general market conditions.

Our actual results may differ materially from management’s expectations. The following discussion and analysis should be read in conjunction with our financial statements included herewith.  This discussion should not be construed to imply that the results discussed herein will necessarily continue in the future, or that any conclusion reached herein will necessarily be indicative of actual operating performance in the future. Such discussion represents only the best present assessment of our management.

The forward-looking statements speak only as of the date on which they are made, and except to the extent required by federal securities laws, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

General

Since inception through December 31, 2010, NaturalNano was a development stage company. Effective January 1, 2011, the Company has diverged from reporting as a development stage company as a result of the business combination with Combotexs. Our primary mission is to develop and exploit technologies in the area of advanced materials science, with an emphasis on additives to industrial and consumer products, taking advantage of technological advances we have developed in-house. These technologies include a specific focus on nanoscale materials using modifications to tubular and spherical materials found in clay. Our strategy is to develop patentable processes and technologies related to these nanoscale materials and to develop products in the polymers and plastics industries as well as the composites, cosmetics, household products and agrichemical industries.

Combotexs was dedicated to building upon the pioneering work of NaturalNano, to commercialize and distribute a wide variety of products incorporating materials that utilize nanotubes found in halloysite clay. From consumer packaged goods to industrial cleaning solutions and medical procedural checklists, nano technology is helping to make these products more effective and less expensive.

NaturalNano is domiciled in the state of Nevada as a result of the merger with Cementitious Materials, Inc. (“CMI”), which was completed on November 29, 2005.

16

Liquidity and Capital Resources

Liquidity and Going Concern

Going Concern – The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company incurred a net loss for the nine months ended September 30, 2012 of $1,058,275 and had negative working capital of $5,814,193 and a stockholders’ deficiency of $6,012,136 at September 30, 2012. Since inception the Company’s growth has been funded through a combination of convertible debt from private investors and from cash advances from its former parent and majority shareholder Technology Innovations, LLC. These factors, among others, may indicate that the Company will be unable to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations, to obtain additional financing, renegotiate the terms of existing financing obligations and ultimately to attain successful operations. The ability to successfully achieve those items is uncertain.

As of September 30, 2012, the Company had $3,611,972 in principal that was outstanding and past due under the terms of the Senior Secured Convertible Notes and Promissory Notes with Platinum Partners Long Term Growth IV (“Platinum”), Platinum Advisors and Longview Special Financing, Inc. (“Longview”). The Company entered into various Senior Secured Convertible Notes and Promissory Note obligations during the period from 2007 through 2010 with Platinum, Platinum Advisors and Longview, the holders of the Company’s primary debt obligations since 2007. The outstanding principal and all accrued and unpaid interest on these obligations was due and payable in full on various dates between March 6, 2009 and January 1, 2011. Platinum and Platinum Advisors have granted waivers of default, extended the due dates of all the outstanding principal balances to January 31, 2013, and waived the application of the 16% default interest rate. Additionally Platinum and Platinum Advisors waived the automatic adjustment of the conversion rate for past and future S-8 stock issuances made for compensation and payments of services. Longview has granted waivers of default, extended the due dates of all the outstanding principal balances to January 31, 2013, and waived the application of the 16% default interest rate. Additionally, Longview waived the automatic adjustment of the conversion rate for past and future S-8 stock issuances made for compensation and payments of services.

As of September 30, 2012, the Company had $251,000 in principal that was outstanding and due under the terms of the Convertible Note with Cape One. Through a series of forbearance agreements, the Convertible Note matures and all outstanding principal is due and payable on January 31, 2013.

As of September 30, 2012, the Company continued to require waivers for debt covenant violations and extensions of maturity dates. Refer to Note 2 for lenders waivers and maturity extensions received from the lenders.

Operating activities

Net cash used in operating activities in the nine months ended September 30, 2012 and 2011 was $104,732 and $79,209, respectively. Cash used in 2012 versus 2011 is up over 32%. The primary driver of this increase the net loss generated in the first nine months of 2012 was $561,169 higher than the prior year period.   Total non-cash adjustments to reconcile the net loss incurred to the cash used in operations aggregated $556,227 in the first nine months of 2012 and $519,800 in first nine months of 2011, an increase of approximately $35,000, offsetting the increased loss.  Also, in 2012 the Company’s accounts payable and accrued expenses have increased by $404,284 due to the lack of cash inflows necessary to satisfy these obligations.  In 2011 the Company managed to decrease accounts payable and accrued expenses by $62,233, resulting in a net positive working capital adjustment of approximately $465,000 further offsetting the increased loss.  The Company continues to actively monitor spending and cash outflows in an effort to reduce costs until continuing revenue sources are developed. The Company is actively seeking opportunities to reduce expenses and improve its liquidity position. We expect total consolidated spending in 2012 to continue to be greater than the 2011 levels, and we will continue to invest in product and commercialization efforts as our cash position and liquidity allow.

Investing activities

There was no net cash used in investing activities in the nine months ended September 30, 2012 and 2011, respectively.

Financing Activities

Net cash provided from financing activities in the nine months ended September 30, 2012 and 2011 was $103,000 and $80,000, respectively. The cash flows from financing activities in the nine months of 2012 were the receipt of $79,000 in proceeds from Platinum Long Term Growth IV and $24,000 in proceeds from Longview Special Finance. The cash flows from financing activities in the first nine months of 2011 were $37,250 in proceeds from Longview Special Finance and $42,750 in proceeds from Platinum Long Term Growth IV.

Critical Accounting Policies and Estimates

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires us to make assumptions that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and related disclosures. Our actual results may differ from these estimates.

Refer to the Company’s December 31, 2011 report on Form 10K for a complete discussion of the critical accounting policies which have not changed during the first nine months ended September 30, 2012.

17

Comparison of Statement of Operations for the three months ended September 30, 2012 and 2011

Revenue and Gross Profit

During the three months ended September 30, 2012 and 2011, the Company recorded $16,158 and $30,136, respectively in consolidated revenue. Third quarter 2011 revenue included $2,000 from shipments of Nanotechnology based products and $28,136 from Medical Board products. Third quarter 2012 revenue included $6,783 from shipments of Nanotechnology based products and $9,375 from Medical Board products. Consolidated cost of goods sold was $3,667 and $12,399 for the shipments completed in the respective quarters. Gross profit of $12,491 and $17,737 was realized for the three months ended September 30, 2012 and 2011, respectively.

The reduction in the Medical Boards sales year over year is a result of the reduction of sales staff for the medical checklist boards business in addition to the changes to the relationship with Combotexs and the new supply agreement with the related party. Gross margin realized in the three months ended September 30, 2012 was 77% compared to 59% for three months ended September 30, 2011. The variance is attributable to the increase in shipments of Nanotechnology products, which have a higher margin, over Medical Board products which have a much lower margin. The Company expects that it will experience significant variations in gross margins with its Nanotechnology products as it continues to introduce to market and develop new products and related applications.  The Company expects that competitive pricing will be a continuing challenge as new products are developed and introduced and product acceptance and the Company’s production reputation develops. 

	For the three months ended September 30,				Variance Increase
Sales, Cost of Goods, and Gross Profit	2012		2011		(decrease)
Halloysite based products	$	6,783	$	2,000	$	4,783
Medical Boards		9,375		28,136		(18,761	)
		16,158		30,136		(13,978	)
Halloysite cost of goods		749		355		394
Medical Boards cost of goods		2,918		12,044		(9,126	)
Consolidated Gross Profit	$	12,491	$	17,737	$	(5,246	)

Operating Expenses

Research and development expenses for the three months ended September 30, 2012 were $21,377 compared to $39,556 for the three months ended September 30, 2011.  The reduction in costs is attributed to the reduction in depreciation due to the life of several long lived assets and the reduction in the cost for patent maintenance costs.

	For the three months ended September 30,				Variance increase
Research and Development	2012		2011		(decrease)
Consulting services	$	5,200	$	4,688	$	512
Patent costs & licensing fees		910		2,580		(1,670	)
Depreciation		5,401		22,457		(17,056	)
Rent & utilities		8,346		8,397		(51	)
All other		1,520		1,434		86
	$	21,377	$	39,556	$	(18,179	)

18

Total general and administrative expenses for the three months ended September 30, 2012 was $93,549 as compared to $115,069 for the three months ended September 30, 2011. The decrease is a result of a combination of activities that changed year over year. There is only one employee in 2012 as opposed to three in 2011 thus reducing salaries and benefits. Management continues to actively assess the Company’s operating structure with the objective align cash expenditures and expenses with growth in total revenue.

	For the three months ended September 30,				Variance increase
General and Administrative	2012		2011		(decrease)
Salaries & benefits	$	48,602	$	62,521	$	(13,919	)
Consulting services		5,751		7,588		(1,837	)
Legal & professional fees		21,214		15,000		6,214
Depreciation & amortization of intangible assets		-		240		(240	)
Insurance expense		969		1,076		(107	)
Shareholder expense		12,057		11,383		674
Travel & Entertainment		1,855		2,202		(347	)
State tax		25		775		(750	)
All other		3,076		14,284		(11,208	)
	$	93,549	$	115,069	$	(21,520	)

Other (Expense) Income

Other expense consists of interest expense on convertible and promissory notes outstanding and other debt related financing and amortization expenses considered components of interest expense for financial reporting. The loss on modification of debt relates to the expense recorded as a result of forbearance agreements and changes to the conversion rates of the preferred shares held by Platinum and Longview as well as the change to the conversion rate of the convertible debt held by Platinum, Longview and Cape One (see Note 2).

	For the three months ended September 30,						Variance increase
Other (Expense) Income	2012			2011			(decrease)
Interest to Senior convertible and promissory notes	$	(75,692	)	$	(82,409	)	$	(6,717	)
Interest to Subordinated Secured Convertible Notes		(11,457	)		(14,758	)		(3,301	)
Interest earned on cash		-			2			2
	$	(87,149	)	$	(97,165	)	$	(10,016	)
Net gain on derivative liability	$	534		$	80,179		$	(79,645	)
Loss on forgiveness/modification of debt	$	(163,566	)	$	(30,000	)	$	(133,566	)

During the first quarter of 2009 and in accordance with EITF 07-05, certain warrants and the embedded conversion of feature associated with the 8% convertible debt were recognized as derivative instruments and as such were re-characterized as derivative liabilities. SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities” (“SFAS 133”) requires that the fair value of these liabilities be re-measured at the end of every reporting period with the change in value reported in the statement of operations. The re-measurement of these derivative liabilities resulted in a gain of $534 in the third quarter of 2012 and a gain of $78,722 during the third quarter of 2011.

Comparison of Statement of Operations for the nine months ended September 30, 2012 and 2011

Revenue and Gross Profit

During the nine months ended September 30, 2012 and 2011, the Company recorded $86,581 and $233,951, respectively in revenue. For the nine months ending September 30, 2012 $31,250 came from Medical Board sales and the $55,331 from shipments of Nanotechnology based product samples; the sales for the same period 2011 came from $162,491 of Medical Board sales and $71,460 from shipments of Nanotechnology based product samples. The related cost of goods sold was $17,653 and $70,351 for these shipments completed in the respective quarters. Gross profit of $68,928 and $163,600 was realized for the nine months ended September 30, 2012 and 2011, respectively.

19

The reduction in the Medical Boards sales year over year is a result of the reduction of sales staff for the medical checklist boards business in addition to the changes to the relationship with Combotexs and the new supply agreement with the related party. Gross margin realized in the nine months ended September 30, 2012 was 80% compared to 70% for nine months ended September 30, 2011. The variance is attributable to the increase in shipments of Nanotechnology products as a percentage of sales, which have a higher margin, over Medical Board products which have a much lower margin. The Company expects that it will experience significant variations in gross margins with its Nanotechnology products as it continues to introduce to market and develop new products and related applications.  The Company expects that competitive pricing will be a continuing challenge as new products are developed and introduced and product acceptance and the Company’s production reputation develops.

	For the nine months ended September 30,				Variance increase
Sales, Cost of Goods, and Gross Profit	2012		2011		(decrease)
Halloysite based products	$	55,331	$	71,160	$	(15,829	)
Medical Boards		31,250		162,791		(131,541	)
		86,581		233,951		(147,370	)
Halloysite cost of goods		3,880		21,544		(17,664	)
Medical Boards cost of goods		13,773		48,807		(35,034	)
Consolidated Gross Profit	$	68,928	$	163,600	$	(94,672	)

Operating Expenses

Total research and development expenses for the nine months ended September 30, 2012 were $90,084 compared to $122,741 for the nine months ended September 30, 2011.  The reduction in costs is attributed to the negotiated reduction in rent for the Emerson Street facility in addition to the reduction in depreciation due to the life of several long lived assets. This is partially offset by the slight increase in spending on patent maintenance costs.

	For the nine months ended				Variance
	September 30,				increase
Research and Development	2012		2011		(decrease)
Consulting services	$	15,462	$	13,387	$	2,075
Patent costs and licensing fees		5,561		1,933		3,628
Depreciation		39,454		75,010		(35,556	)
Rent & utilities		24,112		26,961		(2,849	)
All other		5,495		5,450		45
	$	90,084	$	122,741	$	(32,657	)

Total general and administrative expenses for the nine months ended September 30, 2012 were $268,437 as compared to $306,766 for the nine months ended September 30, 2011. Salaries and benefits are reduced in 2012 because there is only one employee as opposed to three in the same period of 2011. In addition there is only one external board member in 2012 as opposed to three in 2011 which reduces the shareholder and board expense. These items are offset by several transactions from 2011. In 2011 the Company negotiated the reduction in costs of the quarterly review by the external auditors and received the New York State tax refund of $60,073 which partially offsets the costs of recertifying the Company’s legal status in the state of Nevada for the prior three years ($9,935), during the same first nine months. Management continues to actively assess the Company’s operating structure with the objective of aligning cash expenditures and expenses with growth in total revenue.

20

	For the nine months ended					Variance
	September 30,					increase
General and Administrative	2012		2011			(decrease)
Salaries & Benefits	$	143,500	$	194,529		$	(51,029	)
Consulting services		27,119		33,538			(6,419	)
Legal & professional fees		45,714		15,000			30,714
Depreciation & amortization of intangible assets		-		720			(720	)
Insurance expense		2,762		3,258			(496	)
Shareholder expense		29,637		20,638			8,999
Travel and entertainment		7,313		9,177			(1,864	)
State tax		1,784		(48,723	)		50,507
All other		10,608		78,629			(68,021	)
	$	268,437	$	306,766		$	(38,329	)

Other (Expense) Income

Other expense consists of interest expense on various debt instruments and related amortization of deferred financing and debt discount expenses which are considered components of interest expense for financial reporting.

During the first nine months of 2012 amortization of the maturing debt discount was $0 as compared to $1,799 in the first nine months of 2011. As of December 31, 2011 the discount was fully amortized. In April 2011, the Company received a settlement of $31,589 on an insurance claim submitted in July 2010 for a June 29, 2010 warehousing fire at a vendor location for inventory damaged in the fire. Included in interest expense during the nine months ended September 30, 2012, the Company incurred $24,221 of expense related to additional shares issued upon the conversion of interest into common shares. The loss on modification of debt relates to the expense recorded as a result of forbearance agreements and changes to the conversion rates of the preferred shares held by Platinum and Longview as well as the change to the conversion rate of the convertible debt held by Platinum, Longview and Cape One (see Note 2).

	For the nine months ended						Variance
	September 30,						increase
Other (Expense) Income	2012			2011			(decrease)
Amortization of debt discount	$	-		$	(1,799	)	$	(1,799	)
Interest on Senior convertible and promissory notes		(263,417	)		(244,194	)		19,223
Interest to Subordinated Secured Convertible Notes		(32,233	)		(32,050	)		183
Amortization of financing costs		-			(3,815	)		3,815
Interest earned on cash		-			6			6
	$	(295,650	)	$	(281,852	)	$	13,798
Net gain (loss) on derivative liability	$	534		$	41,927		$	(41,393	)
Income from insurance settlement	$	-		$	31,589		$	31,589
Net loss on forgiveness/modification of debt	$	(473,566	)	$	(21,050	)	$	452,516

The Company adopted ASC 815, “Determining Whether an Instrument (or Embedded Feature) is indexed to an Entity’s Own Stock,” effective January 1, 2009. During the first nine months of 2012 and 2011, respectively, the Company recognized a net gain of $534 and a net gain of $41,927 relating to the changes in fair market value for these derivative liabilities.

21

As of March 1, 2011 the Company had $225,000 in principal that was outstanding and due under the terms of the 10% Subordinated Secured Convertible Promissory Agreement (the “Convertible Note”) with Cape One Financial LP (“Cape One”). On March 15, 2011 the Company and Cape One entered into a forbearance agreement which altered the due date of the Convertible Note from March 1, 2011 to June 30, 2011.  As consideration for this forbearance, Cape One will be paid $30,000 which was added to the principal balance of the note.  In addition, the interest rate on the outstanding amount during the forbearance period will be adjusted from 10% to 18%. The forbearance agreement was considered and accounted for as a modification of debt and resulted in a loss of $30,000 for the three months ended March 31, 2011 reported in the statement of operations. Effective June 30, 2011, the Company and Cape One entered into a forbearance agreement which altered the due date of the Convertible Note from June 30, 2011 to October 1, 2011. Effective September 30, 2011, the Company and Cape One entered into another forbearance agreement which altered the due date of the Convertible note from October 1, 2011 to November 22, 2011. As consideration for this forbearance, Cape One will be paid $30,000 which will be added to the principal balance of the note. This forbearance agreement was considered and accounted for as a modification of debt and resulted in a loss of $30,000 for the three months ended September 30, 2011 reported in the statement of operations. Effective January 17, 2012, the Company entered into a forbearance agreement which extends the due date of all the outstanding principal and interest balances to April 16, 2012.  As consideration for this forbearance, Cape One will be paid $25,000 which will be added to the principal balance of the note. The forbearance agreement was considered and accounted for as modification of debt and a loss of $25,000 for the three months ending March 31, 2012 and reported in the statement of operations. Effective April 16, 2012, the Company entered into a forbearance agreement which extends the due date of all the outstanding principal and interest balances to July 01, 2012. Effective June 30, 2012, the Company entered into a forbearance agreement which extends the due date of all the outstanding principal and interest balances to September 30, 2012.  As consideration for this forbearance, Cape One will be paid $30,000 which will be added to the principal balance of the note. The forbearance agreement was considered and accounted for as modification of debt and a loss of $30,000 for the three months ending June 30, 2012 and reported in the statement of operations.

By way of a forbearance agreement effective as of September 30, 2012, Cape One has extended the due date of all the outstanding principal and interest balances to January 31, 2013.  In consideration for this forbearance, the conversion feature of this notes have been changed from a fixed conversion rate of $0.085 per share to a variable rate of 75% of the lowest of the 1, 5, or 10 day VWAP for the Company’s common stock. These adjustments are not expected to have a significant impact on the expected cash flows of the debt as a result of the lack of shares issuable to convert the entire balance and the uncertainty of the Company’s ability to repay the full amounts due. Accordingly, the obligations were not recorded at fair value at the date of modification, which is estimated to be less than the carrying value both before and after the modification. The revised conversion price was considered when determining the value of the derivative liability associated with this debt.

Longview has granted waivers of default on its notes, extended the due dates of all the outstanding principal balances and waived the application of the 16% default interest rate.  Additionally, Longview waived the automatic adjustment of the conversion rate for past and future S-8 stock issuances made for compensation and payments of services. As consideration for this forbearance agreement, effective January 1, 2012, Longview will be paid $50,000 which will be added to the principal balance of the note. The forbearance agreement was considered and accounted for as modification of debt and a loss of $50,000 for the three months ending March 31, 2012 and reported in the statement of operations. Effective April 16, 2012, the Company entered into a forbearance agreement which extends the due date of all the outstanding principal and interest balances to July 1, 2012. In consideration for their forbearance, Longview will be paid $50,000 which will be added to the principal balance of the note. This forbearance will be considered and accounted for as a modification of debt and a loss of $50,000 for the three months ending June 30, 2012 and reported in the statement of operations. Effective June 15, 2012, the Company entered into a forbearance agreement which extended the due date of all the outstanding principal and interest balances to September 30, 2012. In consideration for their forbearance, Longview will be paid $30,000 which will be added to the principal balance of the note. This forbearance was considered and accounted for as a modification of debt and a loss of $30,000 for the three months ending June 30, 2012 and reported in the statement of operations.

Platinum has granted waivers of default on its notes, extended the due dates of all the outstanding principal balances and waived the application of the 16% default interest rate.  Additionally, Platinum waived the automatic adjustment of the conversion rate for past and future S-8 stock issuances made for compensation and payments of services. As consideration for this forbearance agreement, effective December 31, 2011, Platinum will be paid $125,000 which will be added to the principal balance of the note. The forbearance agreement was considered and accounted for as modification of debt and a loss of $125,000 for the three months ending December 31, 2011 and reported in the statement of operations. Effective April 16, 2012, the Company entered into a forbearance agreement which extended the due date of all the outstanding principal and interest balances to July 1, 2012. Effective July 16, 2012, the Company entered into a forbearance agreement which extended the due date of all the outstanding principal and interest balances to September 30, 2012.

22

Platinum Advisors has granted waivers of default on its notes, extended the due dates of all the outstanding principal balances and waived the application of the 16% default interest rate.  Additionally, Platinum waived the automatic adjustment of the conversion rate for past and future S-8 stock issuances made for compensation and payments of services. As consideration for this forbearance agreement, effective December 31, 2011, Platinum will be paid $125,000 which will be added to the principal balance of the note. The forbearance agreement was considered and accounted for as modification of debt and a loss of $125,000 for the three months ending December 31, 2011 and reported in the statement of operations. Effective April 16, 2012, the Company entered into a forbearance agreement which extends the due date of all the outstanding principal and interest balances to July 1, 2012. In consideration for their forbearance, Platinum Advisors will be paid $125,000 which will be added to the principal balance of the note. This forbearance will be considered and accounted for as a modification of debt and a loss of $125,000 for the three months ending June 30, 2012 and reported in the statement of operations. Effective July 25, 2012, the Company entered into a forbearance agreement which extends the due date of all the outstanding principal and interest balances to September 30, 2012.

By way of forbearance agreements effective as of September 30, 2012, Platinum, Platinum Advisors and Longview have granted waivers of default, extended the due dates of all the outstanding principal balances to January 30 or 31, 2013, and waived the application of the 16% default interest rate. In consideration for their forbearance, the conversion features of these notes have been changed from a fixed conversion rate of $0.085 per share to a variable rate of 75% of the lowest of the 1, 5, or 10 day VWAP for the Company’s common stock. These adjustments are not expected to have a significant impact on the expected cash flows of the debt as a result of the lack of shares issuable to convert the entire balance and the unvertainty of the Company’s ability to repay the full amounts due. Accordingly, the obligations were not recorded at fair value at the date of modification, which is estimated to be less than the carrying value both before and after the modification. The revise conversion price was considered when determining the value of the derivative liabiliey associated with this debt. Also in consideration for their forbearance the conversion rate of the Preferred C and Preferred B shares held by Platinum and Longview has been changed from 9.41 common shares per share of preferred to 160 common shares per share of preferred. Due to there not being sufficient common shares authorized to satisfy the conversion of all the preferred shares, they are required to be recorded as temporary equity at their issuance date fair value which resulted in an increase in the balanced presented for preferred stock of $163,566. This amount was recognized as a loss on modification of debt on our consolidated statement of operations for the three month period ended September 30, 2012.

23

Item 4. - Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company’s management is responsible for establishing and maintaining effective disclosure controls and procedures. Our Chief Executive Officer has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including the CEO as appropriate, to allow timely decisions regarding required disclosure.

Based on this evaluation, and in light of the material weaknesses in our internal control over financial reporting that are discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011 our Chief Executive Officer has concluded that our disclosure controls and procedures were not effective. The material weaknesses consist of an insufficient complement of qualified accounting personnel and controls associated with segregation of duties and ineffective controls associated with identifying and accounting for complex and non-routine transactions in accordance with U.S. generally accepted accounting principles.

The Company did not maintain a sufficient complement of qualified accounting personnel and controls associated with the segregation of duties were ineffective. During the fourth quarter of 2008 and the first half of 2009 the Company experienced the resignations in the positions of controller, Chief Financial Officer and Chief Executive Officer. These roles have been filled since the first quarter of 2009 by part time and contract staffing. To address the material weaknesses the Company performed additional analyses and other post-closing procedures to ensure our consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). Notwithstanding these material weaknesses, management believes that the financial statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial condition, result of operations and cash flows for the periods presented.

There can be no assurance, however, that our disclosure controls and procedures will detect or uncover all failures of persons within the Company and its consolidated subsidiaries to disclose material information otherwise required to be set forth in our periodic reports. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable, not absolute, assurance of achieving their control objectives.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

24

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

There have been no material developments to the legal proceeding disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

Effective as of September 30, 2012 the Company entered into various Forbearance Agreements with Platinum Long Term Growth IV LLC and Platinum Advisors LLC relating to the Company’s default on various terms and conditions with borrowing agreements. Platinum Long Term Growth IV LLC and Platinum Advisors LLC agreed to not take any action or exercise or move to enforce any rights or remedies provided for in the various loan documents or otherwise available to it, under law or equity, due to the events of default under the existing Notes until January 31, 2013 unless extended by the lenders in their discretion.

Effective as of September 30, 2012 the Company entered into a Forbearance Agreement with Platinum Long Term Growth LLC due to the Company’s default on various terms and conditions under the following borrowing agreements:

$2,750,000 8% Senior Secured Notes due March 6, 2009,

$150,000 8% Senior Secured Notes due March 6, 2009,

$59,500 8% Senior Secured Notes due January 31, 2010,

$190,000 8% Senior Secured Promissory Note due January 31, 2010,

$136,375 8% Senior Secured Promissory Note due January 31, 2010,

$5,000 8% Senior Secured Promissory Note due June 30, 2009,

$15,000 8% Senior Secured Promissory Note due June 30, 2009,

$25,000 16% Senior Secured Promissory Note due October 12, 2009, and

one or more secured bridge notes in the current principal amount of $254,673 (together the “Notes”).

Also, effective as of September 30, 2012 the Company entered into a Forbearance Agreement with Platinum Advisors LLC relating to the Company’s default on $97,500 of 8% Senior Secured Notes due March 6, 2009.

Effective as of September 30, 2012 the Company entered into a Forbearance Agreement with Longview Special Finance Inc. relating to the Company’s default on various terms and conditions with borrowing agreements. Longview Special Finance Inc.  agreed to not take any action or exercise or move to enforce any rights or remedies provided for in the various loan documents or otherwise available to it, under law or equity, due to the events of default under the existing Notes until January 31, 2013 unless extended by Longview Special Finance Inc. at their discretion. Due to the Company’s default on various terms and conditions under the following borrowing agreements:

$500,000 8% Senior Secured Notes due March 6, 2009,

$20,000 8% Senior Secured Notes due March 6, 2009,

$30,000 Senior Secured Promissory Note due January 31, 2010,

$25,500 Senior Secured Promissory Note due January 31, 2010,

$34,750 16% Senior Secured Promissory Note due January 31, 2010,

$40,000 16% Senior Secured Promissory Note due November 1, 2009,

$3,846 Senior Secured Promissory Note due January 1, 2011,

$3,077 Senior Secured Promissory Note due January 15, 2011,

$9,000 Senior Secured Promissory Note due January 15, 2011,

$35,000 Senior Secured Promissory Note due June 30, 2011,

$2,250 Senior Secured Promissory Note due December 31, 2011, and

$24,000 Senior Secured Promissory Note due September 30, 2012.

These Forbearance Agreements also extend to the Registration Rights Agreement entered into by the Company on March 7, 2007. Platinum Long Term Growth, Platinum Advisors and Longview Special Finance have agreed to forbear from demanding payments defined in these agreements until January 31, 2013, respectively.

As of December 31, 2009, the Company was not in compliance with certain debt covenants of the Subordinated Secured Convertible Note including limitations on the use of proceeds.  On March 20, 2010 the Company received a waiver from the Cape One Financial LP (“Cape One”) indicating that the Lender will not demand payment of principal, default interest and liquidated damages as a result of non-compliance with any existing covenant violations through January 1, 2011. On March 15, 2011, the Company entered into a forbearance agreement with Cape One which extended the due date from March 1, 2011 to June 30, 2011. As consideration for this forbearance, Cape One will be paid $30,000 which will be added to the principal balance of the note. In addition, the interest rate on the outstanding amount during the

25

forbearance period will be adjusted to 18%. Effective June 30, 2011, the Company entered into a forbearance agreement with Cape One which extended the due date from June 30, 2011 to October 1, 2011. Effective September 30, 2011, the Company and Cape One entered into another forbearance agreement which altered the due date of the Convertible note from October 1, 2011 to November 22, 2011. As consideration for this forbearance, Cape One will be paid $30,000 which will be added to the principal balance of the note. This forbearance agreement was considered and accounted for as a modification of debt and resulted in a loss of $30,000 for the three months ended September 30, 2011 reported in the statement of operations. On September 30, 2012, the Company entered into a forbearance agreement with Cape One which extended the due date from September 30, 2012 to January 31, 2013.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

26

Item 6. Exhibits.

Exhibit No.	Description	Location
10.119	Letter Agreement effective as of September 30, 2012 with Platinum Advisors LLC regarding their forbearance with respect to the $97,500 8% Senior Secured Promissory Note due March 6, 2009.	**
10.120	Letter Agreement effective as of September 30, 2012 with Platinum Long Term Growth IV, LLC regarding their forbearance with respect to the $2,750,000 8% Senior Secured Promissory Note due March 6, 2009, issued on or about March 6, 2007, the $150,000 8% Senior Secured Promissory Note due March 6, 2009, issued on or about August 4, 2008, the $190,000 Senior Secured Promissory Note due January 31, 2010, issued on or about September 29, 2008, the $59,500 Senior Secured Promissory Note due January 31, 2010, issued on or about October 31, 2008 and one or more secured bridge notes in the current principal amount of $325,634 (together the “Notes”).	**
10.121	Letter Agreement effective as of September 30, 2012 with Cape One Financial regarding their forbearance with respect to the $225,000 10% Senior Secured Convertible Note due March 1, 2010.	**
10.122	Letter Agreement effective as of September 30, 2012 with Longview Special Finance Inc. regarding their forbearance with respect to  the $500,000 8% Senior Secured Promissory Note due March 6, 2009, issued on or about March 6, 2007, the $20,000 8% Senior Secured Promissory Note due March 6, 2009, issued on or about August 4, 2008, the $30,000 Senior Secured Promissory Note due January 31, 2010, issued on or about September 29, 2008, the $25,500 Senior Secured Promissory Note due January 31, 2010, issued on or about October 31, 2008, the $34,750 16% Senior Secured Promissory Note due January 31, 2010 issued on or about April 3, 2009, the $40,000 16% Senior Secured Promissory Note due November 1, 2009 issued on or about October 22, 2009, and one or more secured bridge notes in the current principal amount of $77,173.	**
31.1	Certification of principal executive officer and principal accounting officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002	**
32.1	Certification of principal executive officer and principal accounting officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002	**
101	Interactive data files formatted in XBRL (eXtensible Business Reporting Language):  (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statement of Stockholders Deficiency (iv) the Consolidated Statements of Cash Flows, and (v) the Notes to the Consolidated Financial Statements.	**
	101.INS    XBRL Instance Document
	101.SCH   XBRL Taxonomy Extension Schema Document
	101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
	101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
	101.LAB   XBRL Taxonomy Extension Label Linkbase Document
	101.PRE    XBRL Taxonomy Extension Presentation Linkbase Document
*	Previously filed
**	Filed herewith

27

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		NaturalNano, Inc.
Date:	November 19, 2012	/s/ James Wemett
		James Wemett
		President and Director (Principal Executive, Financial and Accounting Officer)

28

EX-10.119

EX-10.120

EX-10.121

EX-10.122

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER

PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002

I, James Wemett, certify that:

1) I have reviewed this quarterly report on Form 10-Q of NaturalNano, Inc. (the “registrant”) for the period ended September 30, 2012,

2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4) As the registrant's certifying officer I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5) As the registrant's certifying officer, I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 19, 2012

By:	/s/ James Wemett
Name:	James Wemett
Title:	President
	(Principal Executive, Financial and Accounting Officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of NaturalNano, Inc. (the "Company") on Form 10-Q for the period ended September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report"), I, James Wemett, President of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 19, 2012

By:	/s/ James Wemett
Name:	James Wemett
Title:	President
	(Principal Executive, Financial and Accounting Officer)

XML

SUBSEQUENT EVENTS (Details Textual) (USD $)				9 Months Ended		1 Months Ended	9 Months Ended
	Sep. 30, 2012	Dec. 31, 2011	Oct. 16, 2012 Platinum Partners Long Term Growth I V [Member]	Sep. 30, 2012 Alpha Capital Partners [Member]	Oct. 19, 2012 Alpha Capital Partners [Member]	Oct. 19, 2012 Longview Special Financing Inc. [Member]	Sep. 30, 2012 Series C Preferred Stock [Member] Platinum Partners Long Term Growth I V [Member]	Oct. 16, 2012 Series C Preferred Stock [Member] Platinum Partners Long Term Growth I V [Member]
Common Stock, shares issued	60,652,399	23,403,670	5,676,800		3,100,000
Conversion of Stock, Shares Converted				3,800,000			35,207
Conversion Rate Of Shares						$ 0.0012
Interest Payable					$ 3,720
Conversion Shares Per Convertible Shares								160

XML

DERIVATIVE LIABILITY (Details Textual) (USD $)	1 Months Ended	9 Months Ended	12 Months Ended
	Jan. 31, 2011 Chief Executive Officer [Member]	Sep. 30, 2012 10% Subordinated Secured Convertible Note	Dec. 31, 2011 10% Subordinated Secured Convertible Note	Nov. 30, 2009 10% Subordinated Secured Convertible Note
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.0425	0.0425
Debt Conversion, Converted Instrument, Warrants or Options Issued		2,647,059	2,647,059
Debt Instrument, Interest Rate, Stated Percentage				10.00%
Warrants Granted	882,353
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	$ 0.17

XML

NOTES PAYABLE (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Notes Payable (Note 2)	$ 3,862,972	$ 4,433,557
Senior Secured Promissory Note [Member]
Notes Payable (Note 2)	477,557	374,557
Senior Secured Convertible Notes [Member]
Notes Payable (Note 2)	3,134,415	3,819,000
Senior Secured Convertible Notes and Promissory Notes [Member]
Notes Payable (Note 2)	$ 251,000	$ 240,000

XML

CONTINGENCIES (Details Textual) (Deferred Compensation, Severance and Vacation Benefits [Member], USD $)	3 Months Ended
	Sep. 30, 2010	Mar. 24, 2009
Deferred Compensation, Severance and Vacation Benefits [Member]
Loss Contingency, Estimate of Possible Loss		$ 331,265
Stock Issued During Period Shares For Deferred Compensation	$ 54,691

XML

NOTES PAYABLE

9 Months Ended

Sep. 30, 2012

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

2.  NOTES PAYABLE

Notes payable consisted of the following:

Notes Payable	September 30, 2012		December 31, 2011
Senior Secured Convertible Notes		3,134,415		3,819,000
Senior Secured Promissory Notes		477,557		374,557
Subordinated Secured Convertible Note at Face Value, net of discount of $0 and $1,799		251,000		240,000
Total	$	3,862,972	$	4,433,557

Senior Secured Convertible Notes

As of September 30, 2012, the Company had $3,134,415 in principal that was outstanding and past due under the terms of the Senior Secured Convertible Notes to Platinum Partners Long Term Growth IV (“Platinum”), Platinum Advisors and Longview Special Financing, Inc. (“Longview”). The Company entered into various Senior Secured Convertible Notes and Promissory Note obligations during the period from 2007 through 2012 with Platinum, Platinum Advisors and Longview, the holders of the Company’s primary debt obligations since 2007. The outstanding principal and all accrued and unpaid interest on these obligations was due and payable in full on various dates beginning March 6, 2009. Platinum and Platinum Advisors have granted waivers of default, extended the due dates of all the outstanding principal balances to January 31, 2013, and waived the application of the 16% default interest rate. In consideration for their forbearance effective April 16, 2012, Platinum Advisors will be paid $125,000 which was added to the principal balance of the note. This forbearance was considered and accounted for as a modification of debt and a loss of $125,000 for the three months ending June 30, 2012 and reported in the statement of operations. By way of two separate forbearance agreements dated January 1, 2012 and April 16, 2012, Longview has granted waivers of default, extended the due dates of all the outstanding principal balances to July 1, 2012, and waived the application of the 16% default interest rate. Additionally, Longview waived the automatic adjustment of the conversion rate for past and future S-8 stock issuances made for compensation and payments of services. In consideration for their forbearance, Longview will be paid $50,000 for the forbearance which was added to the principal balance of the note. These forbearance amounts were considered and accounted for as a modification of debt and a loss of $50,000 for the three months ending March 31, 2012 and June 30, 2012 respectively and reported in the statement of operations. By way of a third forbearance agreement dated June 15, 2012, Longview has granted waivers of default, extended the due dates of all the outstanding principal balances to September 30, 2012, and waived the application of the 16% default interest rate. In consideration for their forbearance, Longview will be paid $30,000 for the forbearance which was added to the principal balance of the note. This forbearance amount was considered and accounted for as a modification of debt and recorded as a loss of $30,000 for the three months ending June 30, 2012 in the statement of operations.

By way of forbearance agreements effective as of September 30, 2012, Platinum, Platinum Advisors and Longview have granted waivers of default, extended the due dates of all the outstanding principal balances to January 30 or 31, 2013, and waived the application of the 16% default interest rate. In consideration for their forbearance, the conversion features of these notes have been changed from a fixed conversion rate of $0.085 per share to a variable rate of 75% of the lowest of the 1, 5, or 10 day volume weighted average price (VWAP) for the Company’s common stock. These adjustments are not expected to have a significant impact on the expected cash flows of the debt as a result of the lack of shares issuable to convert the entire balance and the uncertainty of the Company’s ability to repay the full amounts due. Accordingly, the obligations were not recorded at fair value at the date of modification, which is estimated to be less than the carrying value both before and after the modification. The revised conversion price was considered when determining the value of the derivative liability associated with this debt. Also in consideration for their forbearance the conversion rate of the Preferred C and Preferred B shares held by Platinum and Longview has been changed from 9.41 common shares per share of preferred to 160 common shares per share of preferred. Due to there not being sufficient common shares authorized to satisfy the conversion of all the preferred shares, they are required to be recorded as temporary equity at their issuance date fair value which resulted in an increase in the balance presented for preferred stock of $163,566. This amount was recognized as a loss on modification of debt on our consolidated statement of operations for the three month period ended September 30, 2012.

During the first six months of 2012, until the Reverse Stock Split (see Note 10), the Company issued 1,729,412 and 11,053,941 split adjusted shares of common stock to Platinum in payment of $147,000 of interest expense obligations and $939,585 of principal obligations, respectively, on the Senior Secured Convertible Notes. In accordance with the debt agreement, these shares were issued to Platinum using a split adjusted conversion price of $0.085 per common share. Subsequent to the Reverse Stock Split, the Company issued 3,967,626 shares of common stock to Platinum in payment of $25,393 of interest expense obligations on the Senior Secured Convertible Notes. These shares were issued to Platinum using a conversion price of $0.0064 per common share. The issuance of shares in excess of the conversion rate in place at the time of $0.085 were considered an inducement to convert and resulted in an expense of $24,221 based on the market value at the time the excess shares were issued. This expense is included in interest expense for the three months ended June 30, 2012.

Senior Secured Promissory Notes

As of September 30, 2012, the Company had $477,557 in principal that was outstanding and past due under the terms of Senior Secured Promissory Notes to Platinum Partners Long Term Growth IV (“Platinum”) and Longview Special Financing, Inc. (“Longview”). All borrowings under the Senior Secured Promissory Notes bear interest at the rate of 8% per annum and are payable on January 30 or 31, 2013 in accordance with the forbearance agreements mentioned above.

Additions to Senior Secured Promissory Notes in 2012 are as follows:

- On February 10, 2012, the Company borrowed $25,000 from Platinum.

- On March 5, 2012, the Company borrowed $12,000 from Platinum.

- On April 16, 2012, the Company borrowed $15,000 from Platinum.

- On May 11, 2012, the Company borrowed $20,000 from Platinum.

- On July 20, 2012, the Company borrowed $7,000 and $24,000 respectively from Platinum and Longview.

Subordinated Secured Convertible Note

As of March 1, 2011 the Company had $225,000 in principal that was outstanding and due under the terms of the 10% Subordinated Secured Convertible Promissory Agreement (the “Convertible Note”) with Cape One Financial LP (“Cape One”). On March 15, 2011 the Company and Cape One entered into a forbearance agreement which altered the due date of the Convertible Note from March 1, 2011 to June 30, 2011.  As consideration for this forbearance, Cape One will be paid $30,000 which was added to the principal balance of the note.  In addition, the interest rate on the outstanding amount during the forbearance period will be adjusted from 10% to 18%. The forbearance agreement was considered and accounted for as a modification of debt and resulted in a loss of $30,000 for the three months ended March 31, 2011 reported in the statement of operations. Effective June 30, 2011, the Company and Cape One entered into a forbearance agreement which altered the due date of the Convertible Note from June 30, 2011 to October 1, 2011. Effective September 30, 2011, the Company and Cape One entered into another forbearance agreement which altered the due date of the Convertible note from October 1, 2011 to November 22, 2011. As consideration for this forbearance, Cape One will be paid $30,000 which will be added to the principal balance of the note. This forbearance agreement was considered and accounted for as a modification of debt and resulted in a loss of $30,000 for the three months ended September 30, 2011 reported in the statement of operations. Effective January 17, 2012, the Company entered into a forbearance agreement which extends the due date of all the outstanding principal and interest balances to April 16, 2012.  As consideration for this forbearance, Cape One will be paid $25,000 which will be added to the principal balance of the note. The forbearance agreement was considered and accounted for as modification of debt and a loss of $25,000 for the three months ending March 31, 2012 and reported in the statement of operations. Effective April 16, 2012, the Company entered into a forbearance agreement which extends the due date of all the outstanding principal and interest balances to July 01, 2012. Effective June 30, 2012, the Company entered into a forbearance agreement which extends the due date of all the outstanding principal and interest balances to September 30, 2012.  As consideration for this forbearance, Cape One will be paid $30,000 which will be added to the principal balance of the note. The forbearance agreement was considered and accounted for as modification of debt and a loss of $30,000 for the three months ending June 30, 2012 and reported in the statement of operations.

By way of a forbearance agreement effective as of September 30, 2012, Cape One has extended the due date of all the outstanding principal and interest balances to January 31, 2013.  In consideration for this forbearance, the conversion feature of this notes have been changed from a fixed conversion rate of $0.085 per share to a variable rate of 75% of the lowest of the 1, 5, or 10 day VWAP for the Company’s common stock. These adjustments are not expected to have a significant impact on the expected cash flows of the debt as a result of the lack of shares issuable to convert the entire balance and the uncertainty of the Company’s ability to repay the full amounts due. Accordingly, the obligations were not recorded at fair value at the date of modification, which is estimated to be less than the carrying value both before and after the modification. The revised conversion price was considered when determining the value of the derivative liability associated with this debt.

During the first six months of 2012, until the Reverse Stock Split (see Note 10), the Company issued 352,941 and 524,118 shares of common stock to Cape One in payment of $30,000 of principal obligations and $44,550 of interest expense obligations, respectively, on the 10% Convertible Note. In accordance with the debt agreement, these shares were issued to Cape One using a split adjusted conversion price of $0.085 per common share. Subsequent to the Reverse Stock Split, the Company issued 2,187,500 shares of common stock to Cape One in payment of $14,000 of principal obligations on the 10% Convertible Note. These shares were issued to Cape One using a conversion price of $0.0064 per common share.

XML

SEGMENT INFORMATION (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Segment profit (loss) from operations	$ (102,435)	$ (136,888)	$ (289,593)	$ (265,907)
Revenues from external customers	16,158	30,136	86,581	233,951
Significant non-cash items:
Loss on modification of debt	(163,566)	(30,000)	(473,566)	(21,050)
Nanotechnology [Member]
Segment profit (loss) from operations	(108,892)	(124,575)	(307,070)	(284,368)
Revenues from external customers	6,783	2,000	55,331	71,460
Revenues from intersegment sales	0	2,580	0	14,760
Interest expense and amortization of debt discount	87,149	24,370	295,650	209,056
Depreciation and amortization	5,041	22,457	39,454	75,010
Significant non-cash items:
Equity based payments	0	13,107	10,800	50,270
Loss on modification of debt	163,566	0	473,566	0
Medical Boards [Member]
Segment profit (loss) from operations	6,457	(12,313)	17,477	18,461
Revenues from external customers	9,375	28,316	31,250	162,491
Revenues from intersegment sales	0	0	0	0
Interest expense and amortization of debt discount	0	0	0	0
Depreciation and amortization	0	240	0	720
Significant non-cash items:
Equity based payments	0	0	0	0
Loss on modification of debt	0	0	0	0
Consolidated [Member]
Segment profit (loss) from operations	(102,435)	(136,888)	(289,593)	(265,907)
Revenues from external customers	16,158	30,136	86,581	233,951
Revenues from intersegment sales	0	2,580	0	14,760
Interest expense and amortization of debt discount	87,149	24,370	295,650	209,056
Depreciation and amortization	5,041	22,697	39,454	75,730
Significant non-cash items:
Equity based payments	0	13,107	10,800	50,270
Loss on modification of debt	$ 163,566	$ 0	$ 473,566	$ 0

XML

51% ACQUISITION of COMBOTEXS, LLC (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Apr. 20, 2010
Cost of goods sold	$ 3,667	$ 12,399	$ 17,653	$ 70,351	$ 36,875
Goodwill					0
Goodwill, Impairment Loss					$ 80,332
Business Acquisition, Percentage of Voting Interests Acquired						51.00%
Chief Executive Officer [Member]
Percentage Of Interest On Supply Agreement					50.00%

XML

SEGMENT INFORMATION (Details Textual)	3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2012
Percentage Of Revenue From Customers	57.00%
Nanotechnology [Member]
Related Party Transaction, Rate		51.00%
Medical Boards [Member]
Percentage Of Revenue From Customers	17.00%
Related Party Transaction, Rate		36.00%

XML

DERIVATIVE LIABILITY (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2011	Dec. 31, 2010
Derivative Liability, Fair Value, Net	$ 21,124	$ 21,658	$ 34,740	$ 76,667
8% Notes conversion feature [Member]
Derivative Liability, Fair Value, Net	17,120	20,531
10% Notes conversion feature and warrants [Member]
Derivative Liability, Fair Value, Net	4,004	1,127
CEO Warrants [Member]
Derivative Liability, Fair Value, Net	$ 0	$ 0

XML

PRINCIPAL BUSINESS ACTIVITY AND SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2012

Principal Business Activity and Significant Accounting Policies [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

1.   PRINCIPAL BUSINESS ACTIVITY AND SIGNIFICANT ACCOUNTING POLICIES

Interim Financial Statements

The consolidated financial statements as of September 30, 2012 and for the three and nine months ended September 30, 2012 and 2011 are unaudited. However, in the opinion of management of the Company, these financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary to present fairly the financial position and results of operations for such interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results to be obtained for a full year. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X for smaller reporting companies.  Accordingly, these financial statements do not include all of the information required by U.S. generally accepted accounting principles for complete financial statements.  These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011. Certain prior period amounts have been adjusted to reflect the Company’s 1-for-17 reverse stock split (see Note 10 Reverse Stock Split, for further details).

Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, we evaluate such estimates. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.

Fair Value of Financial Instruments

Financial instruments include cash and cash equivalents, accounts payable and accrued expenses, notes payable, and derivative liabilities. Fair values for all instruments except for derivative liabilities and convertible notes payable were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values or they are receivable or payable on demand. The fair value of the derivative liabilities is discussed further in Note 6. The fair value of the Company’s convertible notes payable is estimated be less than the carrying value at September 30, 2012 based upon overall value of the company, lack of authorized shares underlying the conversion of the instruments, and the lack of liquid market for the volume of shares issuable upon conversion of the entire outstanding balance.

Basis of Consolidation

The consolidated financial statements include the accounts of NaturalNano, Inc. (“NaturalNano” or the “Company”), a Nevada corporation, and its wholly owned subsidiary NaturalNano Research, Inc. (“NN Research”) a Delaware corporation. As of April 20, 2010 the consolidated financial statements reflect the acquisition of a 51% controlling interest in Combotexs, LLC, (“Combotexs”), a privately held New York limited liability company, pursuant to the terms of the Equity Purchase Agreement executed with Worldwide Medical Solutions LLC (“WMS”) (Refer to Note 4). All significant inter-company accounts and transactions have been eliminated in consolidation.

Description of the Business

NaturalNano (the “Company”), located in Pittsford, New York, is engaged in the development and commercialization of material science technologies with an emphasis on additives to polymers and other industrial and consumer products by taking advantage of technology advances developed in-house. The Company’s current activities are directed toward research, development, production and marketing of its proprietary technologies relating to the treatment and separation of nanotubes from halloysite clay and the development of related commercial applications for:

• cosmetics, health and beauty products

• polymers, plastics and composites

Combotexs was a technology company organized on October 28, 2009 that marketed Error Prevention/Safety Checklist Boards and Safety Training to hospitals and other industries such as healthcare, petrochemical and mining.  Combotexs also had certain marketing and distribution agreements for various household products.  The Company acknowledges the acquisition of Combotexs as a short term source for revenue, cash flow and a method of incorporating nanotubes found in halloysite clay into Combotexs products.

During the fourth quarter of 2011, the Company determined that the relationship with Combotexs was not operating in the manner it was intended. The sales were not to the volume expected and the continued operations, as structured, were not sustainable. During the month of December, the board of directors authorized the Company CEO to wind down the operations of Combotexs resulting in a write down of assets and the inventory revalued and assumed by NaturalNano. No further activity will occur with Combotexs beyond December 31, 2011 and the entity is expected to be legally dissolved in 2012.

During the fourth quarter of 2011, the Company entered into a supply agreement with another company, which is 50% owned by NaturalNano’s CEO, to manufacture and sell Error Prevention/Safety Checklist Boards which the related party will then market to the end user. NaturalNano will continue to outsource the manufacture of the boards to a third-party and then re-sell them to the new company. Accordingly, the Company will still have continuing cash flows from the business in 2012 and beyond.

NaturalNano is domiciled in the state of Nevada as a result of the merger with Cementitious Materials, Inc., (“CMI”), which was completed on November 29, 2005.

Liquidity and Going Concern

Going Concern – The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company incurred a net loss for the nine months ended September 30, 2012 of $1,058,275 and had negative working capital of $5,184,193 and a stockholders’ deficiency of $6,012,136 at September 30, 2012. Since inception the Company’s growth has been funded through a combination of convertible debt from private investors and from cash advances from its former parent and majority shareholder Technology Innovations, LLC. These factors, among others, may indicate that the Company will be unable to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations, to obtain additional financing, renegotiate the terms of existing financing obligations and ultimately to attain successful operations. The ability to successfully achieve those items is uncertain.

As of September 30, 2012, the Company continued to require waivers for debt covenant violations and extensions of maturity dates. Refer to Note 2 for lenders waivers and maturity extensions received from the lenders.

QETC rebate for fiscal year ended December 31, 2009

The QETC tax rebate for 2009 had been in audit since its filing in September of 2010. The Company received notice in March 2011 that the audit was complete and that the rebate for 2009 would be for $60,073. NaturalNano received the first payment of $43,615 in March of 2011 and that amount was reflected in the financial statements for the first quarter of 2011. The Company received the final payment of $16,458 on April 14, 2011 and that amount was reflected in the financial statements for the second quarter of 2011. These amounts were presented as a reduction of general and administrative expenses.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

Loss Per Share

Basic loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share gives effect to dilutive convertible preferred stock, convertible debt, options and warrants outstanding during the period. Shares to be issued upon the exercise of these instruments have not been included in the computation of diluted loss per share as their effect is anti-dilutive based on the net loss incurred.

As of September 30, 2012, there were approximately 2.7 billion shares underlying preferred stock, convertible debt, outstanding options and warrants that could potentially dilute future earnings. As the company has only 294,117,647 common shares authorized, of which only approximately 225 million are available for future issuance, there is not an adequate number of common shares authorized to satisfy all outstanding preferred stock, convertible debt and outstanding option and warrants. These potentially dilutive shares have been limited by certain debt and equity agreements with Platinum, Platinum Advisors, Longview and Technology Innovations LLC (“TI”). These agreements provide limitations on the conversion of the dilutive instruments such that the number of shares of Common Stock that may be acquired by the holder upon conversion of such instruments shall be limited to ensure that following such conversion the total number of shares of Common Stock then beneficially owned by the holder does not exceed 4.99% of the total number of issued and outstanding shares of Common Stock.

XML

DERIVATIVE LIABILITY (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Fair value - beginning	$ 21,658	$ 76,667
Loss recognized in Q1	0	67,914
Gain Recognized in Q2	0	(29,662)
Gain recognized in Q3	(534)	(80,179)
Fair value - ending	$ 21,124	$ 34,740

XML

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2012	Dec. 31, 2011
Assets
Cash	$ 0	$ 1,732
Accounts receivable	8,885	11,536
Inventory	24,875	20,593
Prepaid expenses and other current assets	11,370	10,033
Total current assets	45,130	43,894
Property and equipment, net	4,997	44,451
Total non-current assets	4,997	44,451
Total Assets	50,127	88,345
Liabilities and Stockholders' Deficiency
Notes Payable (Note 2)	3,862,972	4,433,557
Accounts payable	524,459	498,080
Accrued expenses	86,350	98,851
Accrued interest	361,769	307,283
Accrued payroll	855,157	736,181
Deferred revenue	70,000	70,000
Registration rights liability	82,489	82,489
Derivative liability	21,124	21,658
Total current liabilities	5,864,320	6,248,099
Other long term liabilities	30,000	34,000
Total Liabilities	5,894,320	6,282,099
Stockholders' Deficiency
Common Stock - $.001 par value 294,117,647 authorized, issued and outstanding 60,652,399 and 23,403,670, respectively	60,652	17,138
Additional paid in capital	21,184,872	19,983,595
Noncontrolling interest in subsidiary	14,264	14,264
Accumulated deficit	(27,271,924)	(26,213,649)
Total stockholders' deficiency	(6,012,136)	(6,193,754)
Total Liabilities and Stockholders' Deficiency	50,127	88,345
Series B Preferred Stock [Member]
Stockholders' Deficiency
Preferred Stock - $.001 par value, 10 million shares authorized	22,204	648
Series C Preferred Stock [Member]
Stockholders' Deficiency
Preferred Stock - $.001 par value, 10 million shares authorized	$ 145,739	$ 4,250

XML

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIENCY) [Parenthetical]	9 Months Ended
	Sep. 30, 2012
Range of Per share value of Common stock granted for services	0.005 to $.007

XML

INCENTIVE STOCK PLANS (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2012	Dec. 31, 2011
Outstanding at January 1, 2012, shares	741,373
Cancelled/Forfeited, shares	(18,236)
Options outstanding at September 30, 2012, shares	723,137	741,373
Options exercisable at September 30, 2012, shares	723,137
Outstanding at January 1, 2012, weighted average exercise price	$ 3.52
Options outstanding at September 30, 2012, weighted average exercise price	$ 3.53	$ 3.52
Options exercisable at September 30, 2012, weighted average exercise price	$ 3.53
Options outstanding, weighted average remaining life-years	3 years 3 months 25 days	4 years
Options exercisable, weighted average remaining life-years	3 years 3 months 25 days

XML

DERIVATIVE LIABILITY (Tables)

9 Months Ended

Sep. 30, 2012

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Liabilities at Fair Value [Table Text Block]

The fair value of the derivatives is as follows:

Derivative Liability	September 30, 2012		December 31, 2011
8% Notes conversion feature	$	17,120	$	20,531
10% Notes conversion feature and warrants		4,004		1,127
CEO warrants		-		-
Total	$	21,124	$	21,658

Schedule Of Liabilities Carried At Fair Value Measured Using Significant Unobservable Inputs Table Text Block

The following table provides a roll forward of the liabilities carried at fair value measured using significant unobservable inputs (level 3).

	For the nine months ended
	September 30,
	2012			2011
Fair value – beginning	$	21,658		$	76,667
Loss  recognized in Q1		-			67,914
Gain recognized in Q2		-			(29,662	)
Gain recognized in Q3		(534	)		(80,179	)
Fair value – ending	$	21,124		$	34,740

XML

INCENTIVE STOCK PLANS (Details Textual)	Sep. 30, 2012
2005 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	823,530
2007 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,000,000
2008 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	47,058,824
2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,176,471
2011 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,470,589
2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,764,706

XML

PRINCIPAL BUSINESS ACTIVITY AND SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Mar. 31, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Apr. 20, 2010
Business Acquisition, Percentage of Voting Interests Acquired							51.00%
Net loss attributable to controlling interest	$ (352,616)	$ (176,577)		$ (1,058,275)	$ (497,106)
Working Capitail Deficit	5,184,193			5,184,193
Total stockholders' deficiency	(6,012,136)			(6,012,136)		(6,193,754)
Weighted Average Number of Shares Outstanding, Diluted				2,700,000,000
Qetc Tax Rebate			$ 43,615	$ 60,073
Common Stock, shares authorized	294,117,647			294,117,647		294,117,647
Common Stock, Capital Shares Reserved for Future Issuance	225,000,000			225,000,000
Chief Executive Officer [Member]
Percentage Of Interest On Supply Agreement						50.00%

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net loss attributable to controlling interest	$ (1,058,275)	$ (497,106)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	39,454	75,730
Amortization of discount on convertible notes	0	1,799
Amortization of deferred financing costs	0	3,815
Non-cash gain on forgiveness of debt	0	(38,950)
Fair value adjustment of derivative liabilities	(534)	(41,927)
Issuance of stock for services	10,800	33,150
Issuance of stock for interest	24,221	415,650
Issuance of warrants for services	8,720	8,720
Loss on modification of debt	473,566	60,000
Income (loss) from non-controlling interest in subsidiary	0	1,813
Changes in operating assets and liabilities:
Increase in inventory	(4,282)	(39,790)
Increase in accounts receivable	2,651	1,587
Decrease (increase) in other current assets	(1,337)	5,303
(Decrease) increase in accounts payable, accrued payroll and accrued expenses	404,284	(62,233)
Decrease in deferred revenue	0	(2,270)
Decrease in other liability	(4,000)	(4,500)
Net cash used in operating activities	(104,732)	(79,209)
Cash flows from financing activities:
Proceeds from senior secured promissory notes	103,000	80,000
Proceeds from unsecured promissory notes	0	18,080
Payment on unsecured promissory notes	0	(18,080)
Net cash provided by financing activities	103,000	80,000
Increase (decrease) in cash	(1,732)	791
Cash at beginning of period	1,732	6,861
Cash at end of period	0	7,652
Supplemental disclosure of cash flow information:
Cash paid for interest during the period	0	5,671
Schedule of non-cash investing and financing activities:
Common stock issued for convertible notes	983,585	80,000
Common stock issued for accrued interest	216,943	0
Conversion of preferred shares into common shares	15,669	13,200
Transfer of preferred shares to temporary equity (in shares)	$ 4,376	$ 0

XML

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Sep. 30, 2012	Dec. 31, 2011
Preferred Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000,000	10,000,000
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized	294,117,647	294,117,647
Common Stock, shares issued	60,652,399	23,403,670
Common Stock, shares outstanding	60,652,399	23,403,670
Series B Preferred Stock [Member]
Preferred Stock, aggregate liquidation preference	$ 322	$ 1,295
Preferred Stock, shares issued	161,250	647,500
Preferred Stock, shares outstanding	161,250	647,500
Series C Preferred Stock [Member]
Preferred Stock, aggregate liquidation preference	$ 8,455	$ 8,500
Preferred Stock, shares issued	4,214,793	4,250,000
Preferred Stock, shares outstanding	4,214,793	4,250,000

XML

REVERSE STOCK SPLIT

9 Months Ended

Sep. 30, 2012

Reverse Stock Split [Abstract]

Reverse Stock Split [Text Block]

10. REVERSE STOCK SPLIT

On June 14, 2012, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Nevada, to effect a 1-for-17 reverse stock split of its common stock, or the Reverse Stock Split. This action had previously been approved by the Company’s Board of Directors on March 23, 2012. As a result of the Reverse Stock Split, every seventeen shares of the Company’s pre-reverse split common stock were combined and reclassified into one share of its common stock. No fractional shares were issued in connections with the Reverse Stock Split. Stockholders who would have been entitled to receive a fractional share in connection with the Reverse Stock Split received one whole share. The par value and other terms of the common stock were not affected by the Reverse Stock Split.

The Company’s authorized shares immediately prior to the Reverse Stock Split totaled 5,000,000,000. These were adjusted to 294,117,647. The Company’s shares outstanding immediately prior to the Reverse Stock Split totaled 732,073,557. These were adjusted to 43,063,150 shares outstanding as a result of the Reverse Stock Split. The Company’s common stock began trading at its post-Reverse Stock Split price at the beginning of trading on June 14, 2012. Share, per share, and stock option amounts for all periods presented within this quarterly report on Form 10-Q and the December 31, 2011 Balance Sheet amounts for common stock and additional paid-in-capital have been retroactively adjusted to reflect the Reverse Stock Split.

XML

DOCUMENT AND ENTITY INFORMATION	9 Months Ended
	Sep. 30, 2012	Nov. 16, 2012
Entity Registrant Name	NaturalNano, Inc.
Entity Central Index Key	0000863895
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	nnan
Entity Common Stock, Shares Outstanding		69,429,199
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2012
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2012

XML

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2012

Subsequent Events [Abstract]

Subsequent Events [Text Block]

11. SUBSEQUENT EVENTS

Subsequent to September 30, 2012 and prior to the filing of this report, the following occurred:

Stock Transactions

· On October 16, 2012, 5,676,800 shares of common stock were issued to Platinum Long Term Growth IV, LLC who elected to convert 35,480 shares of Series C preferred shares at the conversion rate of 160 common shares per each Series C share.

· On October 19, 2012, 3,100,000 shares of common stock were issued to Alpha Capital who elected to convert $3,720 of interest due Longview at $0.0012 per share.

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Income:
Revenue	$ 16,158	$ 30,136	$ 86,581	$ 233,951
Cost of goods sold	3,667	12,399	17,653	70,351
Gross profit	12,491	17,737	68,928	163,600
Operating expenses:
Research and development	21,377	39,556	90,084	122,741
General and administrative	93,549	115,069	268,437	306,766
Operating Expenses, Total	114,926	154,625	358,521	429,507
Loss from Operations	(102,435)	(136,888)	(289,593)	(265,907)
Other income (expense):
Interest expense, net	(87,149)	(97,165)	(295,650)	(281,852)
Net gain on derivative liability	534	80,179	534	41,927
Net loss on forgiveness/modification of debt	(163,566)	(30,000)	(473,566)	(21,050)
Gain on insurance settlement	0	0	0	31,589
Nonoperating Income (Expense), Total	(250,181)	(46,986)	(768,682)	(229,386)
Consolidated net loss	(352,616)	(183,874)	(1,058,275)	(495,293)
Less: Consolidated net (income) loss attributable to noncontrolling interest in subsidiary	0	7,297	0	(1,813)
Consolidated net loss attributable to the controlling interest	(352,616)	(176,577)	(1,058,275)	(497,106)
Less: Preferred stock conversion inducement	0	0	(12,235)	0
Consolidated net loss attributable to common shareholders	$ (352,616)	$ (176,577)	$ (1,070,510)	$ (497,106)
Loss per common share - basic and diluted (in dollars per share)	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.03)
Weighted average shares outstanding (in shares)	55,644,823	18,003,314	42,169,055	15,340,376

XML

SEGMENT INFORMATION

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

5. SEGMENT INFORMATION

The Company's reportable segments are strategic business units that offer different products and services. The Company’s reportable segments are organized, managed and internally reported separately because each business requires different technology and marketing strategies. The Company currently has two operating segments, Nanotechnology and Medical Boards.  A summary of the two segments is as follows:

Nanotechnology	Research, development, production and marketing of its proprietary technologies relating to the treatment and separation of nanotubes from halloysite clay and the development of related commercial applications for cosmetics, health and beauty products and polymers, plastics and composites.
Medical Boards	Production of Error Prevention/Safety Checklist Boards for sale to a related party.

The accounting policies of the segments are the same as those described in the summary of significant accounting policies of the Company.  The Company accounts for intersegment sales and transfers as if the sales or transfers were to third parties, that is, at current market prices. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein.  For purposes of determining segment loss, corporate overhead is primarily included in NaturalNano, other than direct expense of Combotexs.  Approximate information concerning the Company’s operations by reportable segment as of and for the three and nine months ended September 30, 2012 and September 30, 2011 is as follows:

Nanotechnology						Medical Boards					Consolidated
	For the three months ended						For the three months ended					For the three months ended
	September 30,						September 30,					September 30,
	2012			2011			2012		2011			2012			2011
Segment profit (loss) from operations	$	(108,892	)	$	(124,575	)	$	6,457	$	(12,313	)	$	(102,435	)	$	(136,888	)
Revenues from external customers	$	6,783		$	2,000		$	9,375	$	28,136		$	16,158		$	30,136
Revenues from intersegment sales	$	-		$	2,580		$	-	$	-		$	-		$	2,580
Interest expense and amortization of debt discount	$	87,149		$	24,370		$	-	$	-		$	87,149		$	24,370
Depreciation and amortization	$	5,041		$	22,457		$	-	$	240		$	5,041		$	22,697
Significant non-cash items:
Equity based payments	$	-		$	13,107		$	-	$	-		$	-		$	13,107
Loss on modification of debt	$	163,566		$	-		$	-	$	-		$	163,566		$	-
	Nanotechnology						Medical Boards					Consolidated
	For the nine months ended						For the nine months ended					For the nine months ended
	September 30,						September 30,					September 30,
	2012			2011			2012		2011			2012			2011
Segment profit (loss) from operations	$	(307,070	)	$	(284,368	)	$	17,477	$	18,461		$	(289,593	)	$	(265,907	)
Revenues from external customers	$	55,331		$	71,460		$	31,250	$	162,491		$	86,581		$	233,951
Revenues from intersegment sales	$	-		$	14,760		$	-	$	-		$	-		$	14,760
Interest expense and amortization of debt discount	$	295,650		$	209,056		$	-	$	-		$	295,650		$	209,056
Depreciation and amortization	$	39,454		$	75,010		$	-	$	720		$	39,454		$	75,730
Significant non-cash items:
Equity based payments	$	10,800		$	50,270		$	-	$	-		$	10,800		$	50,270
Loss on modification of debt	$	473,566		$	-		$	-	$	-		$	473,566		$	-

Geographic Areas - The Company had no revenue and no long-lived assets in any country other than the United States for any period presented.

Major Customers - During the three months ended September 30, 2012, the Company derived 57% (representing sales to a related party included in the Medical Boards operating segment) and 17% (included in the Nanotechnology operating segment) of its revenue from two different customers. During the nine months ended September 30, 2012, the Company derived 36% (representing sales to a related party included in the Medical Boards operating segment) and 51% (included in the Nanotechnology operating segment) of its revenue from two different customers.

XML

51% ACQUISITION of COMBOTEXS, LLC

9 Months Ended

Sep. 30, 2012

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

4.  51% ACQUISITION of COMBOTEXS, LLC

On April 20, 2010 the Company acquired a 51% interest in Combotexs, LLC, (“Combotexs”), a privately held   New York   limited liability company, pursuant to the terms of an Equity Purchase Agreement executed with Worldwide Medical Solutions LLC (“WMS”) the sole member of Combotexs. Combotexs is a technology company that has had minimal revenue since its inception in October 2009 and markets Error Prevention/Safety Checklist Boards and Safety Training to hospitals and other industries such as healthcare, petrochemical and mining. The Company acknowledges the acquisition of Combotexs as a short term source for revenue, cash flow and a method of incorporating nanotubes found in halloysite clay into Combotexs products.

As a result of the changes in the relationship with Combotexs, the carrying values of the related assets as of December 31, 2011 were evaluated. Certain inventory was sold to the related party, certain demonstration inventory was written off resulting in a $36,875 charge to cost of goods sold, and future cash flows were determined to be inestimable and as a result, the Goodwill was impaired to $0 value resulting in an impairment loss of $80,332 during the year ended December 31, 2011.

During the fourth quarter of 2011, the Company entered into a supply agreement with another company, which is 50% owned by NaturalNano’s CEO, to manufacture and sell Error Prevention/Safety Checklist Boards which the related party will then market to the end user. NaturalNano will continue to outsource the manufacture of the boards to a third-party and then re-sell them to the new company. Accordingly, the Company will still have continuing cash flows from the business in 2012 and beyond.

XML

INCENTIVE STOCK PLANS (Tables)

9 Months Ended

Sep. 30, 2012

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the option activity for the nine months ended September 30, 2012 is presented below:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Life-years
Outstanding at January 1, 2012		741,373		$	3.52		4.00
Cancelled/Forfeited		(18,236	)
Options outstanding at September 30, 2012		723,137		$	3.53		3.32
Options exercisable at September 30, 2012		723,137		$	3.53		3.32

XML

PRINCIPAL BUSINESS ACTIVITY AND SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2012

Principal Business Activity and Significant Accounting Policies [Abstract]

Interim Financial Statements [Policy Text Block]

Interim Financial Statements

The consolidated financial statements as of September 30, 2012 and for the three and nine months ended September 30, 2012 and 2011 are unaudited. However, in the opinion of management of the Company, these financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary to present fairly the financial position and results of operations for such interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results to be obtained for a full year. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X for smaller reporting companies.  Accordingly, these financial statements do not include all of the information required by U.S. generally accepted accounting principles for complete financial statements.  These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011. Certain prior period amounts have been adjusted to reflect the Company’s 1-for-17 reverse stock split (see Note 10 Reverse Stock Split, for further details).

Use of Estimates, Policy [Policy Text Block]

Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, we evaluate such estimates. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Financial instruments include cash and cash equivalents, accounts payable and accrued expenses, notes payable, and derivative liabilities. Fair values for all instruments except for derivative liabilities and convertible notes payable were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values or they are receivable or payable on demand. The fair value of the derivative liabilities is discussed further in Note 6. The fair value of the Company’s convertible notes payable is estimated be less than the carrying value at September 30, 2012 based upon overall value of the company, lack of authorized shares underlying the conversion of the instruments, and the lack of liquid market for the volume of shares issuable upon conversion of the entire outstanding balance.

Consolidation, Policy [Policy Text Block]

Basis of Consolidation

The consolidated financial statements include the accounts of NaturalNano, Inc. (“NaturalNano” or the “Company”), a Nevada corporation, and its wholly owned subsidiary NaturalNano Research, Inc. (“NN Research”) a Delaware corporation. As of April 20, 2010 the consolidated financial statements reflect the acquisition of a 51% controlling interest in Combotexs, LLC, (“Combotexs”), a privately held New York limited liability company, pursuant to the terms of the Equity Purchase Agreement executed with Worldwide Medical Solutions LLC (“WMS”) (Refer to Note 4). All significant inter-company accounts and transactions have been eliminated in consolidation.

Business Description [Policy Text Block]

Description of the Business

NaturalNano (the “Company”), located in Pittsford, New York, is engaged in the development and commercialization of material science technologies with an emphasis on additives to polymers and other industrial and consumer products by taking advantage of technology advances developed in-house. The Company’s current activities are directed toward research, development, production and marketing of its proprietary technologies relating to the treatment and separation of nanotubes from halloysite clay and the development of related commercial applications for:

• cosmetics, health and beauty products

• polymers, plastics and composites

Combotexs was a technology company organized on October 28, 2009 that marketed Error Prevention/Safety Checklist Boards and Safety Training to hospitals and other industries such as healthcare, petrochemical and mining.  Combotexs also had certain marketing and distribution agreements for various household products.  The Company acknowledges the acquisition of Combotexs as a short term source for revenue, cash flow and a method of incorporating nanotubes found in halloysite clay into Combotexs products.

During the fourth quarter of 2011, the Company determined that the relationship with Combotexs was not operating in the manner it was intended. The sales were not to the volume expected and the continued operations, as structured, were not sustainable. During the month of December, the board of directors authorized the Company CEO to wind down the operations of Combotexs resulting in a write down of assets and the inventory revalued and assumed by NaturalNano. No further activity will occur with Combotexs beyond December 31, 2011 and the entity is expected to be legally dissolved in 2012.

During the fourth quarter of 2011, the Company entered into a supply agreement with another company, which is 50% owned by NaturalNano’s CEO, to manufacture and sell Error Prevention/Safety Checklist Boards which the related party will then market to the end user. NaturalNano will continue to outsource the manufacture of the boards to a third-party and then re-sell them to the new company. Accordingly, the Company will still have continuing cash flows from the business in 2012 and beyond.

NaturalNano is domiciled in the state of Nevada as a result of the merger with Cementitious Materials, Inc., (“CMI”), which was completed on November 29, 2005.

Liquidity Disclosure [Policy Text Block]

Liquidity and Going Concern

Going Concern – The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company incurred a net loss for the nine months ended September 30, 2012 of $1,058,275 and had negative working capital of $5,184,193 and a stockholders’ deficiency of $6,012,136 at September 30, 2012. Since inception the Company’s growth has been funded through a combination of convertible debt from private investors and from cash advances from its former parent and majority shareholder Technology Innovations, LLC. These factors, among others, may indicate that the Company will be unable to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations, to obtain additional financing, renegotiate the terms of existing financing obligations and ultimately to attain successful operations. The ability to successfully achieve those items is uncertain.

As of September 30, 2012, the Company continued to require waivers for debt covenant violations and extensions of maturity dates. Refer to Note 2 for lenders waivers and maturity extensions received from the lenders.

Qetc Rebate [Policy Text Block]

QETC rebate for fiscal year ended December 31, 2009

The QETC tax rebate for 2009 had been in audit since its filing in September of 2010. The Company received notice in March 2011 that the audit was complete and that the rebate for 2009 would be for $60,073. NaturalNano received the first payment of $43,615 in March of 2011 and that amount was reflected in the financial statements for the first quarter of 2011. The Company received the final payment of $16,458 on April 14, 2011 and that amount was reflected in the financial statements for the second quarter of 2011. These amounts were presented as a reduction of general and administrative expenses.

Prior Period Reclassification Adjustment, Description

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

Earnings Per Share, Policy [Policy Text Block]

Loss Per Share

Basic loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share gives effect to dilutive convertible preferred stock, convertible debt, options and warrants outstanding during the period. Shares to be issued upon the exercise of these instruments have not been included in the computation of diluted loss per share as their effect is anti-dilutive based on the net loss incurred.

As of September 30, 2012, there were approximately 2.7 billion shares underlying preferred stock, convertible debt, outstanding options and warrants that could potentially dilute future earnings. As the company has only 294,117,647 common shares authorized, of which only approximately 225 million are available for future issuance, there is not an adequate number of common shares authorized to satisfy all outstanding preferred stock, convertible debt and outstanding option and warrants. These potentially dilutive shares have been limited by certain debt and equity agreements with Platinum, Platinum Advisors, Longview and Technology Innovations LLC (“TI”). These agreements provide limitations on the conversion of the dilutive instruments such that the number of shares of Common Stock that may be acquired by the holder upon conversion of such instruments shall be limited to ensure that following such conversion the total number of shares of Common Stock then beneficially owned by the holder does not exceed 4.99% of the total number of issued and outstanding shares of Common Stock.

XML

INCENTIVE STOCK PLANS

9 Months Ended

Sep. 30, 2012

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

8.  INCENTIVE STOCK PLANS

Under the Company’s 2005 Incentive Stock Plan (the “2005 Plan”), the Amended and Restated 2007 Incentive Stock Plan (the “2007 Plan”), the 2008 Incentive Stock Plan (the “2008 Plan”), the 2009 Incentive Stock Plan (the “2009 Plan”), the 2011 Stock Incentive Plan (the “2011 Plan”), and the 2012 Stock Incentive Plan (the “2012 Plan”), officers, employees, directors and consultants may be granted options to purchase the Company’s common stock at fair market value as of the date of grant. Options become exercisable over varying vesting periods commencing from the date of grant and have terms of five to ten years. The plan also provides for the granting of performance-based and restricted stock awards.  The shares of common stock underlying the plans are reserved by the Company from its authorized, but not issued common stock. Such shares are issued by the Company upon exercise by any option holder pursuant to any grant of such shares.

The Plans are authorized to grant awards as follows: the 2005 Plan is authorized to grant up to 823,530 share unit awards, the 2007 Plan is authorized to grant up to 1,000,000 share unit awards, the 2008 Plan is authorized to grant up to 47,058,824 unit share awards, the 2009 Plan is authorized to grant up to 1,176,471 unit share awards, the 2011 Plan is authorized to grant up to 1,470,589 unit share awards and the 2012 Plan is authorized to grant up to 1,764,706 unit share awards.

A summary of the option activity for the nine months ended September 30, 2012 is presented below:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Life-years
Outstanding at January 1, 2012		741,373		$	3.52		4.00
Cancelled/Forfeited		(18,236	)
Options outstanding at September 30, 2012		723,137		$	3.53		3.32
Options exercisable at September 30, 2012		723,137		$	3.53		3.32

XML

DERIVATIVE LIABILITY

9 Months Ended

Sep. 30, 2012

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

6.  DERIVATIVE LIABILITY

The Company’s derivative liabilities as of September 30, 2012 and December 31, 2011 are as follows:

· The debt conversion feature embedded in the Senior Secured Convertible Notes entered into in March 2007, August 2008, September 2008 and October 2008 which contains anti-dilution provisions that would be triggered if the Company issued instruments with rights to the Company’s common stock at prices below this exercise price. Additionally, there are not sufficient authorized common shares to satisfy the conversion of the total debt balance.

· The debt conversion feature and the 2,647,059 million warrants exercisable at $0.0425 per share (split adjusted) granted in connection with the 10% Subordinated Secured Convertible Note entered into in November 2009.  These agreements contain anti-dilution provisions that would be triggered if the Company issued instruments with rights to the Company’s common stock at prices below the exercise price. Additionally, there are not sufficient authorized common shares to satisfy conversion of the total debt balance and warrants.

·

The 882,353 warrant shares granted to the CEO of the Company at an exercise price of $0.17 per share on January 2011 which vest over three years.

The fair value of the derivatives is as follows:

Derivative Liability	September 30, 2012		December 31, 2011
8% Notes conversion feature	$	17,120	$	20,531
10% Notes conversion feature and warrants		4,004		1,127
CEO warrants		-		-
Total	$	21,124	$	21,658

 Fair Value Valuation Hierarchy Measurement

ASC 820 establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:

· Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.

· Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

· Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to measure assets and liabilities at fair value.

A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

The derivative liabilities are measured at fair value using certain estimated factors such as volatility and probability and are classified within Level 3 of the valuation hierarchy. The following table provides a roll forward of the liabilities carried at fair value measured using significant unobservable inputs (level 3).

	For the nine months ended
	September 30,
	2012			2011
Fair value – beginning	$	21,658		$	76,667
Loss  recognized in Q1		-			67,914
Gain recognized in Q2		-			(29,662	)
Gain recognized in Q3		(534	)		(80,179	)
Fair value – ending	$	21,124		$	34,740

XML

STOCKHOLDERS EQUITY

9 Months Ended

Sep. 30, 2012

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

7.  STOCKHOLDERS EQUITY

On January 3, 2011, the Chief Executive Officer, Mr. Jim Wemett was awarded 882,353 warrant shares, each warrant share grants the right to purchase one share of common stock, at an exercise price of $0.17 per warrant share, vesting over three years. The warrants expire January 3, 2016 and contain a cashless exercise provision. The fair value of the warrant on the date of grant was determined using the Black-Scholes model and was measured on the date of grant at $34,879. An expected volatility assumption of 150% has been used based on the volatility of the Company’s stock price utilizing a look-back basis and the risk-free interest rate of 3.36% has been derived from the U.S. treasury yield. The market price of the Company’s common stock on January 3, 2011 was $0.0476 per share. The expiration date used in the valuation model aligns with the warrant life of five years. The dividend yield was assumed to be zero. The fair value of the warrant will be recorded monthly over the 36 month life of the warrant. During the three and nine months ended September 30, 2012, the Company recorded $2,907 and $8,720 respectively of expense for the vested portion of the warrant.

During the first six months of 2012, until the Reverse Stock Split (see Note 10), the Company issued 1,729,412 and 11,053,941 split adjusted shares of common stock to Platinum in payment of $147,000 of interest expense obligations and $939,585 of principal obligations, respectively, on the Senior Secured Convertible Notes. In accordance with the debt agreement, these shares were issued to Platinum using a split adjusted conversion price of $0.085 per common share. Subsequent to the Reverse Stock Split through September 30, 2012, the Company issued 3,967,626 shares of common stock to Platinum in payment of $25,393 of interest expense obligations on the Senior Secured Convertible Notes. These shares were issued to Platinum using a conversion price of $0.0064 per common share. The issuance of shares in excess of the conversion rate in place at the time of $0.085 were considered an inducement to convert and resulted in an expense of $24,221 based on the market value at the time the excess shares were issued. This expense is included in interest expense for the three months ending June 30, 2012.

Prior to the Reverse Stock Split (see Note 10), in 2012 Alpha Capital Anstalt converted 450,000 preferred B shares held by Longview Special Finance into 4,235,294 common shares respectively. Subsequent to the Reverse Stock split on June 18, 2012 Alpha Capital Anstalt converted 12,500 preferred B shares held by Longview Special Finance into 2,000,000 common shares. As the post-split conversion rate for the shares held by Longview Special Finance was 9.41 common shares per 1 share of preferred stock, the excess shares were recorded as an expense attributable to common stockholders in the statement of operations for the three months ended June 30, 2012 at their conversion date market value of $12,235. As a condition of forbearance agreements entered into in Q3 2012, the conversion rate for all outstanding shares of preferred stock was adjusted to 160 common shares for each share of preferred (Note 2). Subsequent to this modification, in Q3 Alpha Capital Anstalt converted 23,750 preferred B shares held by Longview Special Finance into 3,800,000 common shares. Also subsequent to this modification, in Q3 Platinum converted 35,207 preferred C shares into 5,633,191 common shares.

During the first six months of 2012, until the Reverse Stock Split (see Note 10), the Company issued 877,059 shares of common stock to Cape One in payment of $44,500 of interest expense obligations and $30,000 of principal obligations on the Convertible Notes. In accordance with the debt agreement, these shares were issued to Cape One using a conversion price of $0.085 per common share. Subsequent to the Reverse Stock Split through September 30, 2012, the Company issued 2,187,500 shares of common stock to Cape One in payment of $14,000 of principal obligations on the Senior Secured Convertible Notes. These shares were issued to Cape One using a conversion price of $0.0064 per common share.

During the first six months of 2012, the Company issued an aggregate of 1,764,706 shares of common stock to various individuals or entities in connection with professional consulting provided to the Company in an aggregate amount of $10,800.

The Company has issued warrants to purchase shares of its common stock to certain consultants and debt holders. As of September 30, 2012, there were common stock warrants outstanding to purchase an aggregate 4,247,059 shares of common stock pursuant to various warrant grant agreements. In April of 2012, 14,162 warrants originally issued to a consultant in April of 2007 expired unexercised. As a result of the Company not having sufficient shares authorized to satisfy its outstanding convertible and exercisable instruments including these warrants, these warrants should be treated as a liability recorded at their fair value. As the estimated fair value of these warrants as of September 30, 2012 is nearly $0, no liability has been recorded.

On May 20, 2011, June 8, 2011 and August 26, 2011 Alpha Capital Anstalt converted 20,000, 31,250 and 31,250 preferred shares held by Longview Special Finance into 3,200,000, 5,000,000 and 5,000,000 common shares respectively.

As there are not sufficient shares to satisfy the conversion features of all of the Company’s convertible notes payable and convertible preferred stock, the Company does not control the settlement of these convertible securities by delivery of the Company’s own common shares, resulting in the presumption of cash settlement. This results in the carrying value of the outstanding Preferred B and Preferred C shares being classified as temporary equity as of September 30, 2012.

XML

CONTINGENCIES

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

9.  CONTINGENCIES

Legal Proceedings

On March 24, 2009 the Company received a demand notice from an attorney representing a group of certain former employees of the Company, including but not limited to the Company’s former President and Chief Financial Officer, demanding immediate payment of $331,265 for certain deferred compensation, severance and vacation benefits. Each of the former employees cited in the demand notice, as well as other former employees, had executed written agreements during 2008 that allowed the Company to defer certain of these compensation payments. The Company has accrued for earned and unused vacation benefits and deferred payroll costs for amounts electively deferred by these and other former employees as of December 31, 2009. The Company has retained counsel in connection with this demand and continues to evaluate this demand notice and has responded to this demand. No actions or probable settlement discussions between the parties have developed since the filing of this demand. Due to the Company’s current cash and liquidity position discussed above and the current evaluation of the items in the demand notice the timing of future payment of these outstanding amounts is uncertain. No further communication has been had regarding this notice.

During the third quarter ending September 30, 2010, two former employees, one involved in the March 24, 2009 demand, agreed to forgive the Company’s liability to them of $54,691 related to deferred compensation in exchange for shares of common stock.

XML

STOCKHOLDERS EQUITY (Details Textual) (USD $)	3 Months Ended		9 Months Ended				0 Months Ended	1 Months Ended		0 Months Ended	1 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended	0 Months Ended	1 Months Ended	9 Months Ended					1 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Apr. 30, 2012	Jan. 03, 2011	Jun. 08, 2011 Convertible Preferred Stock [Member]	Aug. 26, 2011 Convertible Preferred Stock [Member]	May 20, 2011 Convertible Preferred Stock [Member]	Jun. 08, 2011 Common Stock [Member]	Aug. 26, 2011 Common Stock [Member]	May 20, 2011 Common Stock [Member]	Sep. 30, 2012 Platinum Partners Long Term Growth I V [Member]	Sep. 30, 2012 Platinum Partners Long Term Growth I V [Member] Series C Preferred Stock [Member]	Sep. 30, 2012 Platinum Partners Long Term Growth I V [Member] Senior Secured Convertible Notes [Member]	Sep. 30, 2012 Platinum Partners Long Term Growth I V [Member] Senior Secured Convertible Notes [Member]	Oct. 16, 2012 Platinum Partners Long Term Growth I V [Member] Senior Secured Convertible Notes [Member] Series C Preferred Stock [Member]	Jun. 18, 2012 Alpha Capital Partners [Member]	Sep. 30, 2012 Alpha Capital Partners [Member]	Sep. 30, 2012 Alpha Capital Partners [Member] Series B Preferred Stock [Member]	Sep. 30, 2012 Cape One Financial L P [Member]	Sep. 30, 2012 Cape One Financial L P [Member] Interest Expense [Member]	Sep. 30, 2012 Cape One Financial L P [Member] Convertible Notes [Member]	Jan. 31, 2011 Jim Wemett [Member]	Mar. 31, 2011 Jim Wemett [Member]	Sep. 30, 2012 Jim Wemett [Member]	Jan. 03, 2011 Jim Wemett [Member]
Class of Warrant or Right, Outstanding	4,247,059		4,247,059																								882,353
Class of Warrant or Right, Exercise Price of Warrants or Rights																											$ 0.17
Class Of Warrants Or Rights Vesting Period																											3 years
Class Of Warrants Or Rights Expiration Date																										Jan. 03, 2016
Fair Value Of Warrants Or Rights On The Date Of Grant																											$ 34,879
Fair Value Assumptions Expected Volatility Rate																								150.00%	3.36%
Market Price Of Common Stock						$ 0.0476
Fair Value Assumptions, Expected Term																									5 years
Fair Value Of Warrants Recording Period																											36 months
Long-term Debt, Gross															939,585	939,585
Issuance of warrants for services	2,907		8,720	8,720
Stock Issued During Period Shares New Issues For Interest Expense Debt															3,967,626	1,729,412			450,000
Stock Issued During Period, Shares, Reverse Stock Splits	5,000,000,000		11,053,941													11,053,941
Debt Instrument, Convertible, Interest Expense															25,393	147,000
Debt Instrument, Convertible, Conversion Price															$ 0.0064	$ 0.0064					$ 0.085		$ 85.000
Excess Of Debt Instrument Conversion Rate	$ 0.085		$ 0.085												$ 0.085	$ 0.085
Interest Expense, Debt	24,221														24,221
Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value																		12,500
Shares issued on debt conversion (in shares)																		2,000,000
Stock Issued During Period Conversion Price Per Share	$ 9.41		$ 9.41																$ 4,235,294
Less: Preferred stock conversion inducement	0	0	12,235	0
Stock Issued During Period, Shares, New Issues																					877,059
Stock Issued During Period, Value, New Issues																						44,500	30,000
Stock Issued During Period, Shares, Issued for Services			1,764,706
Stock Issued During Period, Value, Issued for Services	10,800
Class Of Warrant Or Right Expired Unexercised					14,162
Conversion of Stock, Shares Converted							31,250	31,250	20,000					35,207			35,480		3,800,000	23,750
Conversion of Stock, Shares Issued										5,000,000	5,000,000	3,200,000	5,633,191
Debt Conversion, Converted Instrument, Shares Issued																					2,187,500
Debt Conversion, Converted Instrument, Amount																					$ 14,000

XML

SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Approximate information concerning the Company’s operations by reportable segment as of and for the three and nine months ended September 30, 2012 and September 30, 2011 is as follows:

Nanotechnology						Medical Boards					Consolidated
	For the three months ended						For the three months ended					For the three months ended
	September 30,						September 30,					September 30,
	2012			2011			2012		2011			2012			2011
Segment profit (loss) from operations	$	(108,892	)	$	(124,575	)	$	6,457	$	(12,313	)	$	(102,435	)	$	(136,888	)
Revenues from external customers	$	6,783		$	2,000		$	9,375	$	28,136		$	16,158		$	30,136
Revenues from intersegment sales	$	-		$	2,580		$	-	$	-		$	-		$	2,580
Interest expense and amortization of debt discount	$	87,149		$	24,370		$	-	$	-		$	87,149		$	24,370
Depreciation and amortization	$	5,041		$	22,457		$	-	$	240		$	5,041		$	22,697
Significant non-cash items:
Equity based payments	$	-		$	13,107		$	-	$	-		$	-		$	13,107
Loss on modification of debt	$	163,566		$	-		$	-	$	-		$	163,566		$	-
	Nanotechnology						Medical Boards					Consolidated
	For the nine months ended						For the nine months ended					For the nine months ended
	September 30,						September 30,					September 30,
	2012			2011			2012		2011			2012			2011
Segment profit (loss) from operations	$	(307,070	)	$	(284,368	)	$	17,477	$	18,461		$	(289,593	)	$	(265,907	)
Revenues from external customers	$	55,331		$	71,460		$	31,250	$	162,491		$	86,581		$	233,951
Revenues from intersegment sales	$	-		$	14,760		$	-	$	-		$	-		$	14,760
Interest expense and amortization of debt discount	$	295,650		$	209,056		$	-	$	-		$	295,650		$	209,056
Depreciation and amortization	$	39,454		$	75,010		$	-	$	720		$	39,454		$	75,730
Significant non-cash items:
Equity based payments	$	10,800		$	50,270		$	-	$	-		$	10,800		$	50,270
Loss on modification of debt	$	473,566		$	-		$	-	$	-		$	473,566		$	-

XML

NOTES PAYABLE (Details Textual) (USD $)	1 Months Ended	3 Months Ended				9 Months Ended			3 Months Ended	9 Months Ended		3 Months Ended	9 Months Ended		1 Months Ended	9 Months Ended					1 Months Ended	3 Months Ended		9 Months Ended	1 Months Ended					9 Months Ended			3 Months Ended	9 Months Ended		3 Months Ended					9 Months Ended
	Sep. 30, 2012	Sep. 30, 2012	Mar. 31, 2012	Sep. 30, 2011	Mar. 31, 2011	Sep. 30, 2012	Sep. 30, 2011	Apr. 16, 2012	Sep. 30, 2012 Platinum Partners Long Term Growth I V and Platinum Advisors [Member]	Sep. 30, 2012 Platinum Partners Long Term Growth I V and Platinum Advisors [Member]	Apr. 16, 2012 Platinum Partners Long Term Growth I V and Platinum Advisors [Member]	Sep. 30, 2012 Longview Special Financing Inc [Member]	Sep. 30, 2012 Longview Special Financing Inc [Member]	Jul. 16, 2012 Platinum Partners Long Term Growth I V [Member]	Jun. 18, 2012 Alpha Capital Partners [Member]	Sep. 30, 2012 Alpha Capital Partners [Member]	Sep. 30, 2012 Cape One Financial L P [Member]	Sep. 30, 2012 Maximum [Member]	Sep. 30, 2012 Minimum [Member]	Jul. 16, 2012 Senior Secured Promissory Note [Member]	Jul. 20, 2012 Senior Secured Promissory Note [Member] Longview Special Financing Inc [Member]	Sep. 30, 2012 Senior Secured Promissory Note [Member] Longview Special Financing Inc [Member]	Mar. 31, 2012 Senior Secured Promissory Note [Member] Longview Special Financing Inc [Member]	Sep. 30, 2012 Senior Secured Promissory Note [Member] Longview Special Financing Inc [Member]	Jul. 20, 2012 Senior Secured Promissory Note [Member] Platinum Partners Long Term Growth I V [Member]	May 11, 2012 Senior Secured Promissory Note [Member] Platinum Partners Long Term Growth I V [Member]	Apr. 16, 2012 Senior Secured Promissory Note [Member] Platinum Partners Long Term Growth I V [Member]	Mar. 05, 2012 Senior Secured Promissory Note [Member] Platinum Partners Long Term Growth I V [Member]	Feb. 10, 2012 Senior Secured Promissory Note [Member] Platinum Partners Long Term Growth I V [Member]	Sep. 30, 2012 Senior Secured Promissory Note [Member] Platinum Partners Long Term Growth I V [Member]	Jul. 19, 2012 Senior Secured Promissory Note [Member] Platinum Partners Long Term Growth I V [Member]	Jul. 16, 2012 Senior Secured Promissory Note [Member] Platinum Partners Long Term Growth I V [Member]	Sep. 30, 2012 Senior Secured Convertible Notes [Member] Platinum Partners Long Term Growth I V [Member]	Sep. 30, 2012 Senior Secured Convertible Notes [Member] Platinum Partners Long Term Growth I V [Member]	Sep. 30, 2012 Senior Secured Convertible Notes and Promissory Notes [Member]	Sep. 30, 2012 10% Subordinated Secured Convertible Promissory Agreement [Member]	Mar. 31, 2012 10% Subordinated Secured Convertible Promissory Agreement [Member]	Sep. 30, 2011 10% Subordinated Secured Convertible Promissory Agreement [Member]	Mar. 31, 2011 10% Subordinated Secured Convertible Promissory Agreement [Member]	Mar. 01, 2011 10% Subordinated Secured Convertible Promissory Agreement [Member] Cape One Financial L P [Member]	Sep. 30, 2012 10% Convertible Notes [Member] Cape One Financial L P [Member]
Long-term Debt, Gross																									$ 7,000								$ 939,585	$ 939,585	$ 3,134,415					$ 225,000	$ 30,000
Debt Instrument Maturity Date Range Start 1						Mar. 06, 2009
Debt Instrument Extended Maturity Date	Jun. 15, 2012					Sep. 30, 2012																		Sep. 30, 2012														Oct. 01, 2011	Jun. 30, 2011
Debt Intrument Default Interest Rate Waived Off						16.00%				16.00%			16.00%
Debt Instrument Additions To Carrying Amount	30,000	30,000				30,000		25,000			125,000	30,000	30,000									50,000		50,000		20,000	15,000	12,000	25,000							30,000	25,000	30,000	30,000
Gains Losses On Modification Of Debt		30,000	50,000		25,000				125,000			30,000										50,000	50,000													30,000	25,000		30,000
Debt Instrument, Interest Rate, Stated Percentage														75.00%						8.00%						8.00%	8.00%	8.00%	8.00%		8.00%	8.00%
Debt Instrument, Maturity Date																										Sep. 01, 2012	Sep. 01, 2012	Sep. 30, 2012	Sep. 30, 2012										Mar. 01, 2012
Stock Issued During Period Shares New Issues For Interest Expense Debt																450,000																	3,967,626	1,729,412							352,941
Stock Issued During Period, Shares, Reverse Stock Splits		5,000,000,000				11,053,941																												11,053,941
Debt Instrument, Convertible, Interest Expense																																	25,393	147,000							44,550
Shares issued on debt conversion (in shares)															2,000,000															160											524,118
Debt Instrument For Bearance Interest Rate Percentage																																							18.00%
Interest Expense, Debt		24,221																															24,221
Excess Of Debt Instrument Conversion Rate	$ 0.085	$ 0.085				$ 0.085																											$ 0.085	$ 0.085
Proceeds from Issuance of Senior Long-term Debt																					24,000				7,000,000
Debt Instrument, Face Amount	14,000	14,000				14,000
Debt Instrument, Convertible, Conversion Price									$ 0.0064	$ 0.0064							$ 0.085													$ 9.41			$ 0.0064	$ 0.0064							$ 0.085
Debt Instrument, Convertible, Conversion Ratio																		75	0.085
Debt Conversion, Converted Instrument, Shares Issued																	2,187,500
Gains (Losses) On Extinguishment Of Debt		$ (163,566)		$ (30,000)		$ (473,566)	$ (21,050)

XML

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIENCY) (USD $)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2011	$ 23,403	$ 4,898	$ 19,977,330	$ (26,213,649)	$ 14,264	$ (6,193,754)
Balance (in shares) at Dec. 31, 2011	23,403,671	4,897,500
Grant of common stock for services @: $0.005 to $.007 per share	1,765		9,035			10,800
Grant of common stock for services @ $0.001 to $.003 per share (in shares)	1,764,706
Issuance of common stock as interest payment	6,221		234,943			241,164
Issuance of common stock as interest payment (in shares)	6,221,156
Warrant issued for services			8,720			8,720
Shares issued on debt conversion	13,594		969,991			983,585
Shares issued on debt conversion (in shares)	13,594,382
Series B preferred shares converted to common shares	10,035	(486)	(9,549)			0
Series B preferred shares converted to common shares (in shares)	10,035,294	(486,250)
Series C preferred shares converted to common shares	5,633	(35)	(5,598)			0
Series C preferred shares converted to common shares (in dollars per share)	5,633,191	(35,207)
Transfer of preferred shares to temporary equity (in shares)		(4,376)				4,376
Transfer Of Preferred Shares To Temporary Equity		(4,376,043)
Net income (loss) for the nine months ended 09/30/12				(1,058,275)	0	(1,058,275)
Balance at Sep. 30, 2012	$ 60,652	$ 0	$ 21,184,872	$ (27,271,924)	$ 14,264	$ (6,012,136)
Balance (in shares) at Sep. 30, 2012	60,652,399	0

XML

REGISTRATION RIGHTS AGREEMENT

9 Months Ended

Sep. 30, 2012

Registration Rights Agreement [Abstract]

Registration Rights Agreement [Text Block]

3.  REGISTRATION RIGHTS AGREEMENT

On March 7, 2007, the Company entered into a Registration Rights Agreement with the Agent and the other investors, pursuant to which the Company agreed to prepare and file within 60 days of the March 7, 2007 agreement, a registration statement for resale under the Securities Act of 1933, the common stock issuable upon the exercise of the Warrants, in payment of interest on, or upon conversion of, the Notes. The Company further agreed to use its best efforts to cause the Registration Statement to be declared effective 120 days following the March 7, 2007 agreement date, or within 150 days if the Company receives a comment letter from the SEC, and to maintain such Registration Statement for the two year period following this date. This agreement allows for liquidated damages based on a daily amount of 0.0333% of the principal amount of the notes relating to the common stock issuable upon conversion of the Notes included in the Registration Statement.

As of September 30, 2012, the registration statement had not been updated with the requisite SEC filings and as such, the Company was in default of this provision of the Registration Rights Agreement. The lenders have provided the Company with a forbearance agreement related to this default through November 22, 2011. The Company recorded a total of $146,028 in such liquidated damages as of December 17, 2007, the date the registration statement was declared effective. As of December 31, 2007, $63,539 of this obligation was paid in cash and $82,489 was recorded as an accrued liability. The lender has the option to settle the liquidated damages in common stock valued at the average price for the five days prior to the end of a payment period. At September 30, 2012 and December 31, 2011 the outstanding balance for this obligation was $82,489.

XML

REGISTRATION RIGHTS AGREEMENT (Details Textual) (USD $)	1 Months Ended	9 Months Ended
	Dec. 31, 2007	Sep. 30, 2012	Dec. 31, 2011
Liquidation Damages	$ 146,028
Liquidation Damages Paid	63,539
Accrued Liabilities		$ 82,489	$ 82,489
Liquidation Damages Calculation Terms		This agreement allows for liquidated damages based on a daily amount of 0.0333% of the principal amount of the notes relating to the common stock issuable upon conversion of the Notes included in the Registration Statement.

XML

REVERSE STOCK SPLIT (Details Textual)	3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2012	Dec. 31, 2011
Stock Issued During Period, Shares, Reverse Stock Splits	5,000,000,000	11,053,941
Common Stock, shares authorized	294,117,647	294,117,647	294,117,647
Common Stock, shares outstanding	60,652,399	60,652,399	23,403,670
Numerator [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		1
Denominator [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		17
Prior To Reverse Stock Split [Member]
Common Stock, shares outstanding	732,073,557	732,073,557
After Reverse Stock Split [Member]
Common Stock, shares outstanding	43,063,150	43,063,150

XML

NOTES PAYABLE (Tables)

9 Months Ended

Sep. 30, 2012

Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

Notes payable consisted of the following:

Notes Payable	September 30, 2012		December 31, 2011
Senior Secured Convertible Notes		3,134,415		3,819,000
Senior Secured Promissory Notes		477,557		374,557
Subordinated Secured Convertible Note at Face Value, net of discount of $0 and $1,799		251,000		240,000
Total	$	3,862,972	$	4,433,557